US20070044811A1 - Energy based devices and methods for treatment of patent foramen ovale - Google Patents
Energy based devices and methods for treatment of patent foramen ovale Download PDFInfo
- Publication number
- US20070044811A1 US20070044811A1 US11/506,232 US50623206A US2007044811A1 US 20070044811 A1 US20070044811 A1 US 20070044811A1 US 50623206 A US50623206 A US 50623206A US 2007044811 A1 US2007044811 A1 US 2007044811A1
- Authority
- US
- United States
- Prior art keywords
- closure device
- cardiac opening
- catheter
- patch
- adhesive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1492—Probes or electrodes therefor having a flexible, catheter-like structure, e.g. for heart ablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00575—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for closure at remote site, e.g. closing atrial septum defects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00867—Material properties shape memory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
- A61B2018/0025—Multiple balloons
- A61B2018/00261—Multiple balloons arranged in a line
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00273—Anchoring means for temporary attachment of a device to tissue
- A61B2018/00279—Anchoring means for temporary attachment of a device to tissue deployable
- A61B2018/00285—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00273—Anchoring means for temporary attachment of a device to tissue
- A61B2018/00291—Anchoring means for temporary attachment of a device to tissue using suction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00345—Vascular system
- A61B2018/00351—Heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00619—Welding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/0063—Sealing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00696—Controlled or regulated parameters
- A61B2018/00702—Power or energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00791—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00636—Sensing and controlling the application of energy
- A61B2018/00773—Sensed parameters
- A61B2018/00875—Resistance or impedance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1472—Probes or electrodes therefor for use with liquid electrolyte, e.g. virtual electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/361—Image-producing devices, e.g. surgical cameras
- A61B2090/3614—Image-producing devices, e.g. surgical cameras using optical fibre
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2201/00—Properties
- C08L2201/12—Shape memory
Definitions
- the invention generally relates to medical apparatus and methods. More specifically, the invention relates to apparatus and methods for treatment of patent foramen ovale.
- Fetal blood circulation is much different than adult circulation. Because fetal blood is oxygenated by the placenta, rather than the fetal lungs, blood is generally shunted away from the lungs to the peripheral tissues through a number of vessels and foramens that remain patent (i.e., open) during fetal life and typically close shortly after birth. For example, fetal blood passes directly from the right atrium through the foramen ovale into the left atrium, and a portion of blood circulating through the pulmonary artery trunk passes through the ductus arteriosus to the aorta. This fetal circulation is shown in attached FIG. 1 .
- Patent foramen ovale has long been considered a relatively benign condition, since it typically has little effect on the body's circulation. More recently, however, it has been found that a significant number of strokes may be caused at least in part by PFO. In some cases, stroke may occur because a PFO allows blood containing small thrombi to flow directly from the venous circulation to the arterial circulation and into the brain, rather than flowing to the lungs where the thrombi can become trapped and gradually dissolved. In other cases, thrombi might form in the patent channel of the PFO itself and become dislodged when the pressures cause blood to flow from the right atrium to the left atrium. It has been estimated that patients with PFOs who have already had cryptogenic strokes have a 4% risk per year of having another stroke.
- a number of interventional devices for closing PFOs percutaneously have also been proposed and developed. Most of these devices are the same as or similar to ASD closure devices. They are typically “clamshell” or “double umbrella” shaped devices which deploy an area of biocompatible metal mesh or fabric (ePTFE or Dacron, for example) on each side of the atrial septum, held together with a central axial element, to cover the PFO. This umbrella then heals into the atrial septum, with the healing response forming a uniform layer of tissue or “pannus” over the device.
- Such devices have been developed, for example, by companies such as Nitinol Medical Technologies, Inc. (Boston, Mass.) and AGA Medical, Inc. (White Bear Lake, Minn.).
- U.S. Pat. No. 6,401,720 describes a method and apparatus for thoracoscopic intracardiac procedures which may be used for treatment of PFO.
- Methods and apparatus for treatment of patent foramen ovale generally involve use of a catheter having treatment apparatus at its distal end.
- the treatment apparatus includes at least one conductive element disposed at the distal end of the catheter.
- the treatment apparatus may also include a positive stop feature to limit the penetration of the treatment apparatus to a predetermined depth into the PFO.
- the apparatus also includes an energy source, such as a radiofrequency generator, used in conjunction with a closure device.
- Methods generally involve advancing the catheter to position its distal end near the PFO and using the treatment apparatus to secure a closure device to the tissue with energy and/or tissue solder or tissue adhesive to close the PFO.
- the closure device may be a plug that physically covers the PFO.
- the closure device may be a plug inserted selectively into the PFO.
- a method of treating a patent foramen ovale comprises: advancing a catheter device having a proximal end, a distal end and at least one conductive element and closure device near the distal end through vasculature of a patient to position the distal end adjacent the patent foramen ovale; advancing the at least one conductive element and closure device to or into the patent foramen ovale; exposing the at least one conductive element to the closure element and/or to the tissue; and applying energy to the tissue and/or closure device to fix the device to or into the tissue of the PFO.
- advancing the catheter comprises advancing through at least one of a femoral vein, an iliac vein, an inferior vena cava, a brachial vein, an axial vein, a subclavian vein, and a superior vena cava of the patient. In some embodiments, advancing the catheter comprises advancing over a guidewire.
- exposing the at least one conductive element and closure device involves retracting a catheter body of the catheter to expose the at least one conductive element and closure device out of an opening in the catheter body at or near the distal end of the catheter.
- exposing the at least one conductive element and closure device may involve advancing the conductive element and closure device relative to the catheter body.
- the at least one conductive element and closure device may be retracted and advanced as many times as desired.
- any embodiment may include visualization of the PFO and/or tissue surrounding the PFO using one or more visualization devices.
- advancing the at least one conductive element and closure device to or into the PFO optionally includes inserting at least a portion of the at least one conductive element and closure device into the PFO until a positive stop provided on the treatment apparatus engages the peripheral limits of the PFO, limiting penetration depth of the at least one conductive element and closure device.
- a further aspect of advancing the closure device to or into the PFO includes providing a closure device made from a self-expanding bioresorbable, doped matrix and allowing the self expanding material of the closure device to fill and/or span the PFO.
- a self-expanding or expandable matrix that is not bioresorbable may be used.
- advancing the treatment apparatus comprises advancing two or more conductive elements to the PFO and using the two or more conductive elements to apply lateral, dilatory or a combination of both forces to bring the tissue of the septum primum and septum secundum of the PFO into apposition.
- the lateral and/or dilatory forces may bring the tissue of the septum primum and septum secundum into apposition with one or more of the conductive elements, or into apposition with the closure device.
- advancing the closure device comprises spanning the area between the two or more conductive elements with the closure device.
- advancing the closure device may comprise allowing the closure device to self-expand in and/or near the PFO to fill any space left after the primum and secundum are brought into apposition by the two or more conductive elements.
- applying lateral, dilatory or a combination of forces may be achieved by inflating a balloon within the conductive elements, or by incorporating the conductive elements into a balloon.
- Methods for fixing the closure device to the PFO include applying energy to the at least one conductive element of the treatment apparatus via the delivery catheter.
- monopolar radiofrequency energy is applied through the at least one conductive element and the conductively doped closure device, heating the tissue and/or closure device, to fix the closure device to the tissue and close the PFO.
- applying energy to the closure device may cause solder or adhesive-filled compartments within the closure device to rupture, fixing the closure device to the PFO.
- An alternative method includes applying bipolar radiofrequency energy between the at least one conductive element and a ground electrode on the delivery catheter or proximal treatment apparatus to heat the tissue and/or closure device to fix the closure device to the tissue and close the PFO.
- a further method entails applying bipolar radiofrequency energy between the two or more conductive elements of the treatment apparatus to heat the tissue and/or closure device to fix the closure device to the tissue and close the PFO.
- the energy may be conducted from each of the two or more conductive elements of the treatment apparatus into specifically defined conductive pathways of the closure device.
- apparatus for treating PFO comprises an elongate catheter body having a proximal end and a distal end and a treatment apparatus comprised of at least one retractable conductive element movable between a retracted position wherein the conductive element resides wholly within the catheter body and a deployed position wherein at least a portion of the conductive element extends through an opening in the catheter body adjacent the distal end.
- the catheter body is passable over a guidewire.
- the at least one retractable conductive element contains at least one positive stop provided to engage the peripheral limits of the PFO, limiting penetration depth of the at least one conductive element and closure device.
- the at least one retractable conductive element comprises multiple conductive elements.
- the at least one retractable conductive element is movable relative to the catheter body to extend the at least one conductive element through the PFO and retract the conductive element back through the foramen ovale.
- Apparatus for treating a PFO also consist of a closure device, which may include a bioabsorbable or non-resorbable matrix.
- the matrix may include conductive elements to reduce impedance over the desired energy transmission plane and to enhance energy conduction from the energy delivery means to the tissue in order to more predictably and securely affix the closure device to the tissue.
- the closure device may incorporate tissue solders or adhesives. These solders or adhesives may be designed to achieve full adhesion upon energy delivery.
- Conductive elements incorporated into the closure device may include conductive wires.
- conductive elements may comprise patterned doping of conductive particles into specific conductive shapes or pathways within the closure device.
- Example conductive wires may be made from gold, platinum, iridium, or alloys thereof.
- Example doping elements include powdered metals such as tantalum, platinum, gold, iridium, or alloys thereof.
- Example matrices include self expanding collagen, hyaluronic acid, absorbable sponge, matrices of bioabsorbable polymers, and bioresorbable metals, such as iron or nickel alloys.
- Example tissue solders or adhesives include autologous blood, albumin, collagen, fibrin, cyanoacrylates, mussel byssus adhesives, polymer hot melt adhesives or the like. Combinations of several of these solders or adhesives may also be utilized.
- closure devices incorporating conductive elements may include design features such as skirts, flanges or lips which are designed to engage the tissue of the right atrium adjacent to the PFO, acting as a positive stop and as additional retention means.
- the closure device will incorporate deformable non-resorbable frame members in order to facilitate closure device positioning and retention.
- FIG. 1 is a diagram of the fetal circulation
- FIG. 2 is a diagram of a catheter apparatus according to an embodiment of the present invention, having a conductive element and closure device, the catheter passing through the inferior vena cava and right atrium and through the patent foramen ovale;
- FIGS. 3A-3C are a diagram of a catheter apparatus according to an embodiment of the present invention, having a conductive element and closure device;
- FIG. 4 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and positive stops;
- FIGS. 5A-5D are diagrams showing the delivery of devices according to an embodiment of the present invention, wherein lateral force and expanding matrices are used to close a PFO;
- FIG. 6 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements which apply lateral and dilatory force to the PFO;
- FIGS. 7A-7C are diagrams showing the delivery of devices according to an embodiment of the present invention, wherein lateral and dilatory forces and closure devices are used to close a PFO;
- FIG. 8 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements which apply lateral and dilatory force to the PFO via balloon actuation;
- FIG. 9 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and a closure device consisting of a conductively doped matrix;
- FIG. 10 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and a conductive particle-doped closure device, wherein the conductive doping particles form specific conduction pathways;
- FIG. 11 is a diagram of a closure device according to an embodiment of the present invention, having conductive elements and bioresorbable elements;
- FIG. 12 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and a conductive particle-doped closure device wherein the conductive doping particles form specific conduction pathways which are electrically isolated from one another;
- FIG. 13 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and a conductive particle-doped closure device, wherein the conductive doping particles form specific conduction pathways which are electrically isolated from one another in a multi-layer configuration;
- FIG. 14 is a diagram of a catheter apparatus according to an embodiment of the present invention, having a self-expanding, non-resorbable patch closure device;
- FIG. 15 is a diagram of a catheter apparatus according to an embodiment of the present invention, having a balloon-expandable, non-resorbable patch closure device;
- FIG. 16 is a diagram of a catheter apparatus according to an embodiment of the present invention, having non-resorbable patch members and a non-resorbable frame;
- FIG. 17A is a diagram of a catheter apparatus according to an embodiment of the present invention, in position to weld a patch to tissues to close a PFO;
- FIG. 17B is a diagram of a delivery catheter and patch according to an embodiment of the present invention.
- FIGS. 18A and 18B are diagrams of a PFO patch according to an embodiment of the present invention.
- FIG. 19 is a diagram of a locking PFO patch according to an embodiment of the present invention.
- FIG. 20 is a diagram of a PFO patch according to an embodiment of the present invention in position across a PFO;
- FIGS. 21A-21C are diagrams of a catheter apparatus according to an embodiment of the present invention, having a backstop member for positioning a patch in a PFO;
- FIGS. 22A and 22B are diagrams of a catheter apparatus according to an embodiment of the present invention, having an expandable PFO patch and a backstop member;
- FIGS. 23-26 are diagrams of various backstop members for use in catheter apparatus according to various embodiments of the present invention.
- Methods and apparatus of the invention generally provide for treating tissue adjacent a patent foramen ovale (PFO) to cause closure of the foramen.
- the methods and devices typically include a catheter device which can be advanced through the vasculature of a patient to position the distal end of the catheter near the PFO to provide treatment.
- Treatment apparatus disposed at or near the distal end of the catheter can then be used to treat at least a portion of the heart wall tissue surrounding the PFO, to cause the PFO to close.
- the treatment apparatus is used to transmit energy to a closure device and to the tissues surrounding the PFO. The energy causes bonding to occur between the tissue of the PFO and the closure device, which may in turn induce a response in the tissues which causes the PFO to close.
- the treatment apparatus includes one or more conductive elements. Such conductive elements may be retractable into (and extendable out of) the body of the catheter.
- closure devices may be made from bioresorbable materials such as collagen, hyaluronic acids, or various formulations of bioresorbable polymers such as PLLA, PLGA, degradable metals or the like.
- closure devices may comprise one or more non-resorbable materials, such Dacron®, ePTFE, non-degradable metallic weaves such as platinum alloys, gold, nitinol or stainless steel, or composites of several of these materials.
- the closure device may be self expanding or expandable to fill gaps left between the tissues of the PFO after they are brought into apposition for sealing.
- conductive particles are incorporated into the matrix of the closure device to increase conductivity and inductance through the closure device and the tissues of the PFO in order to increase the efficacy and consistency of the closure. These particles may be evenly distributed throughout the matrix of the closure device, or they might be arranged into specifically designed conductive pathways.
- tissue surrounding, encircling or forming a PFO will generally be referred to as “tissue adjacent the PFO” or “PFO tissue” or “tissue surrounding the PFO.”
- a “PFO” itself is actually a foramen, or opening, in tissue of the heart wall between the left and right atria (the interatrial septum), while tissue adjacent the PFO is tissue of the septum primum and the septum secundum that has failed to fuse, thus leaving the foramen ovale patent.
- tissue adjacent the PFO means tissue of the septum primum, tissue of the septum secundum, and/or any other adjacent heart wall tissue upon which an embodiment of the invention may act.
- FIG. 2 shows a catheter system 10 according to an embodiment of the present invention in place across a PFO
- FIGS. 3A-3C demonstrate the use of such a catheter system 10
- catheter system 10 consists of an outer delivery catheter 11 and in inner catheter 12 with at least one treatment apparatus 14 and at least one closure device 16 disposed at its distal tip.
- Treatment apparatus 14 may comprise, for example, at least one conductive element for transmitting energy such as radiofrequency energy to the closure device and to the tissue of the PFO.
- Closure device 16 may be any of the embodiments discussed further below, such as a bioresorbable or non-resorbable matrix or patch, or any other device for closure of a PFO.
- delivery catheter 11 is placed through or into the PFO, with inner catheter 12 having treatment apparatus 14 and closure device 16 housed within it.
- Outer delivery catheter 11 is withdrawn to expose treatment apparatus 14 to the tissues of the PFO.
- Energy is applied via treatment apparatus 14 to closure device 16 to cause closure device 16 and/or tissue solders or adhesives within the matrix of closure device 16 to bond with the tissues of the PFO, securing closure device 16 to the tissue.
- closure device 16 may incorporate conductive or inductive particulate material in order to enhance energy transmission and tissue bonding. Once the bond is complete, energy delivery ceases and the entire delivery system 10 and treatment apparatus 14 are withdrawn from the body, leaving closure device 16 in place.
- Closure device 16 may be constructed of a sponge-like material that will self-seal upon withdrawal of the treatment apparatus from closure device 16 .
- treatment apparatus 14 might be withdrawn from closure device 16 as energy is being applied, sealing the track of the treatment apparatus 14 as it is withdrawn.
- Devices such as those described in FIGS. 2 and 3 A-C will most preferably make use of monopolar radiofrequency (RF) energy transmitted from the conductive elements of the treatment apparatus, through the patient, completing the circuit to a ground pad affixed to the external skin of the patient.
- Control systems within the energy delivery systems may automatically stop energy delivery upon detecting a change in condition of energy delivery, for instance an increase in electrical resistance or impedance within closure device 16 and/or tissues, or an increased energy draw from the treatment apparatus.
- bipolar RF energy may be transmitted from the treatment apparatus.
- other forms of energy may be applied to one or more closure devices and/or to tissues adjacent a PFO, such as but not limited to resistive heating, ultrasound, microwave or laser energy.
- FIG. 4 shows a distal end of one embodiment of a catheter 10 having treatment apparatus 14 comprising two conductive elements, each having an insulated proximal portion 20 , a “positive stop” 22 , and an uninsulated distal energy transmission portion 24 .
- Catheter 10 may also include a ground site 26 for bipolar use.
- a closure device of the types described elsewhere in this disclosure may span the distance between the uninsulated energy transmission portions 24 of the conductive elements.
- Positive stops 22 engage the peripheral limits of the PFO in order to allow passage of treatment apparatus 14 to a predetermined depth within the PFO.
- the multiple conductive elements may be made to separate through spring-action or through positive mechanical means in order to apply lateral forces to the PFO, stretching the tissue of the septum primum and septum secundum and bringing the edges of these tissue structures into apposition.
- FIGS. 5A-5D show the use of a device such as that described in FIG. 4 .
- the system is delivered to the PFO as previously described, and upon reaching the PFO a delivery sheath is withdrawn, exposing the treatment apparatus 14 and positive stop.
- the lateral motion ( FIG. 5B ) of the treatment apparatus 14 and the positive stops 22 assist in bringing the closure device into position within the PFO, and in bringing the tissues of the PFO in apposition to one another.
- the matrix may expand to fill any voids between the tissues of the PFO ( FIG. 5C ).
- Energy is applied to the closure device via the conductive elements of the treatment apparatus 14 , and the delivery system and the treatment apparatus 14 are withdrawn ( FIG. 5D ). Bipolar energy may be applied between the conductive elements or between the elements and the ground site 26 .
- FIGS. 6 and 7 A-C show a treatment apparatus 30 having multiple conductive elements 32 which apply both lateral and dilatory force to the PFO, in order to more forcefully bring a closure device 34 into apposition with the tissues of the PFO.
- closure device 34 which may incorporate any of the features previously disclosed, may form a closed-ended sock-like structure.
- the proximal edge of closure device 34 may be positioned on conductive elements 32 such that when lateral and dilatory forces are exerted on closure device 34 and the tissues of the PFO, the proximal portion of closure device 34 forms a skirt 36 which contacts the tissue of the right atrium peripheral to the PFO.
- energy application may cause a main portion of closure device 34 to adhere to the tunnel of the PFO, while the skirted area 36 adheres to the right atrial tissue surrounding the PFO tunnel.
- FIG. 8 shows an alternative embodiment of a treatment apparatus 40 extended distally from a delivery catheter 42 .
- a balloon 50 exerts dilatory and lateral forces on the PFO and closure device 48 .
- Conductive element retention wires 46 run through small lumens 44 or channels in treatment apparatus 40 and exert lateral forces on balloon 50 , closure device 48 and PFO tissues, to help flatten balloon 50 and conform more closely to the natural geometry of the PFO.
- Retention wires 46 also act as conductive elements for delivery of energy to the closure device and PFO.
- Devices such as those described in FIGS. 4 , 5 A-D, 6 , 7 A-C and 8 may make use of monopolar radiofrequency energy, wherein energy is applied simultaneously to all conductive elements, completing the circuit through an external ground pad affixed to the skin of the patient.
- bipolar energy may be applied to all conductive elements simultaneously, and the circuit completed through a ground element incorporated elsewhere on the delivery system.
- Further embodiments may include applying bipolar energy between two or more conductive elements of the treatment apparatus, which are electrically isolated from one another within the delivery system.
- Control systems may be includes in various embodiments within the energy delivery systems for detecting and/or stopping energy delivery. Such a control system may automatically stop energy delivery upon detecting a change in a condition of energy delivery, for instance an increase in electrical resistance or impedance within the closure device and/or tissues, or an increased energy draw from the treatment apparatus. In some embodiments, a control system will stop energy delivery when a temperature is detected that relates to a sufficient temperature for tissue welding. Such control features may be accomplished by any suitable devices or combinations, such as by thermistors or the like.
- FIG. 9 demonstrates another embodiment of treatment apparatus 60 extending out of a delivery catheter 62 , the latter of which includes an optional electrical ground 63 .
- the closure device 68 is doped with an approximately even distribution of conductive particles 67 within a bioresorbable matrix.
- Conductive particles 67 may include, for example, powders of gold, platinum; steel, tantalum, tungsten, iridium, or alloys or combinations thereof. In any case, it will be desirable for the particle size to be smaller than a red blood cell (about 20 microns) so that upon resorption of the binding matrix of the closure device, individual conductive particles 67 may pass through the body for filtration and expulsion by the liver or kidneys without causing obstruction within the vascular bed.
- conductive particles 67 reduce impedance in the tissues adjacent the PFO and thus assist energy transmission to the tissues.
- FIG. 10 demonstrates another embodiment of treatment apparatus 70 extending from a delivery catheter 72 having an electrical ground 73 .
- specific patterns of doped material 76 are created on a closure device 78 by selectively doping portions of the closure device matrix 78 .
- the doped material pattern 76 may be electrically conductive, or it may simply reduce the electrical resistance or impedance along which a signal might preferentially pass without actually being conductive.
- at least one specific path is created which is in connection with both conducting elements 74 of treatment apparatus 70 . This embodiment will be particularly useful in a monopolar energy delivery arrangement or with bipolar energy delivery when the return path is part of the delivery system (as with ground 73 ).
- FIG. 11 demonstrates an alternative embodiment for an electrically conductive or reduced resistance closure device 80 wherein a woven or braided fabric is created from alternating fibers of bioresorbable fibers 84 and electrically conductive or reduced resistance fibers 82 .
- the electrically conductive or reduced resistance/impedance fibers 82 will be metal fibers, rather than pathways created from selective doping of particles. Any electrically conductive or reduced resistance/impedance wire material will be suitable for the application, such as gold, steel, platinum, copper, a resorbable metal such as an iron or nickel alloy, or the like.
- This closure device can be made to work with either bipolar or monopolar energy delivery, depending on the exact scheme of coupling of the conductive fibers 82 to the conductive elements of the treatment apparatus.
- FIG. 12 shows yet another embodiment of a closure device 90 , having attachment elements 92 for removably coupling closure device with conductive elements of treatment apparatus, one or more insulation zones 94 and two or more selectively doped conductive or reduced resistance or impedance pathways 96 , 98 .
- pathways 96 , 98 are arranged so that at least a first pathway 96 is most closely coupled with one conduction element of the treatment apparatus, and at least a second pathway 98 is most closely coupled with another conduction element of the treatment apparatus, with one or more insulation zones 94 disposed between pathways 96 , 98 .
- This embodiment is particularly suited for bipolar energy transmission.
- FIG. 13 demonstrates a variation of the multiple-pathway arrangement of FIG. 12 .
- a closure device 100 includes an upper conductive layer 102 having at least a first pathway 104 , a middle layer 106 providing insulation, and a lower conductive layer 108 having at least a second pathway 110 .
- the layers are joined to form a composite closure device 100 particularly suited for delivery of bipolar energy.
- upper layer 102 may be uniformly doped to provide conductivity or reduced resistance/impedance with a first electrode
- lower layer 108 may be uniformly doped and most closely coupled with a second electrode, with middle layer 106 again providing electrical isolation.
- the pathway may be made to be in true electrical connection with its intended conduction element, or it may simply be more strongly coupled with a given electrode than with a different electrode.
- True electrical conductivity may be established through the pathway or plane, or the mechanism of increased energy transfer may be that of reducing the impedance of a given path which it is desired for the energy to follow.
- closure devices of the present invention may be entirely bioresorbable, partially bioresorbable, or entirely non-resorbable. Many of the embodiments described above are intended to be bioresporbable but may also be constructed from non-resorbable materials. The descriptions that follow often focus on “patches” for closing a PFO. Typically, these patches will be non-resorbable, but again, bioresorbable or partially resorbable patches are contemplated. Furthermore, a “patch” may comprise any of a number of different closure devices, and therefore, the term patch should not be interpreted to limit the scope of the invention to any one embodiment or configuration. For the purposes of this application, “patch”, “closure device” and the like may be used interchangeably to mean any device for closing a PFO.
- FIGS. 14, 15 and 16 illustrate apparatus and methods for welding patches using variations of normally-closed devices that are inserted into the PFO, expanded to provide secure contact to both sides of the PFO, and welded into place using energy.
- the device is then allowed to collapse back to its unexpanded state, sealing the PFO.
- the device may be actively closed through a mechanical locking mechanism built into the device.
- Energy can be RF, ultrasound, microwave, resistive heating, laser, or any source that causes the device to become irreversibly adhered to the walls of the PFO.
- These devices may be made from a degradable metal or metal/fabric combination, so that after facilitating healing and permanent closure for the PFO, the device degrades and disappears.
- the devices optionally include a non-degradable fabric patch or fitted covering which heals into the surrounding tissue prior to degradation, and serves as a permanent reinforcement and an emboli containment mechanism to prevent embolism in the event that the device erode unevenly.
- Implantation of such self-closing devices can be facilitated by the introduction of protein solders during the welding step to facilitate adhesion and closure.
- a dye such as indocyanine green into the solder to help increase the specificity of the laser activation to the solder site.
- FIG. 14 shows deployment of a self-expanding patch 126 from a catheter device 120 having a delivery catheter 121 , an inner catheter 122 and treatment apparatus 124 including patch 126 and a conductive element 125 .
- Patch 126 expands upon being exposed from delivery catheter 121 and is welded, using conductive element 125 to tissue adjacent the PFO to close the PFO.
- FIG. 15 shows a similar catheter device 130 , having an outer catheter 131 , an inner catheter 132 , and treatment apparatus 134 including a balloon expandable patch 136 , a conductive element 135 and an inflatable balloon 138 .
- patch 136 is expanded into place via balloon 138 and then welded to PFO tissues to close the PFO.
- FIG. 16 shows another embodiment of a catheter device 140 , this embodiment including an outer catheter 141 , an inner catheter 142 , one or more patches 146 and a reinforcement member 148 for helping to hold patches 146 in place within the PFO.
- FIGS. 17-22 illustrate devices which cover the slit-like opening of the PFO like a bike tire patch, bridging from the septum primum to the septum secundum to effect the seal.
- Embodiments include expanding fork-like devices, braided devices which are compressed into disciform patches, and balloon expanded patches. They can be made from traditional graft and patch materials such as Dacron® or ePTFE, from non-degradable metallic weaves such as platinum alloys, gold, nitinol or stainless steel, degradable metallic weaves such as iron or magnesium alloys, degradable polymers such as PLLA, or composites of several of these materials. Adherence can be facilitated by the active introduction during welding or prior impregnation of protein solders into the devices. All energy modalities described above can be used. These devices generally employ a second catheter element which is deployed through the PFO into the left atrium.
- FIGS. 17A and 17B show right atrial cutaway and septum cross-sectional views, respectively, of one embodiment of a tissue-welded patch device for sealing a PFO.
- a patch 150 includes conducting fibers 156 for conducting energy and a covering mesh 154 coupled with fibers 156 .
- Patch 150 is generally delivered by advancing through a delivery catheter 152 via an introducer rod 151 .
- Conducting fibers 156 are coupled to an electrolytic joint 158 for transmission of energy to the wires.
- a portion of patch 150 tucks into the overlap of the septum secundum and the septum primum.
- FIGS. 18A, 18B , 19 and 20 show a mushrooming patch 160 for closing a PFO.
- Patch 160 includes a proximal locking component 162 and a distal locking component 164 for enabling patch 160 to change from a straight configuration ( FIG. 18A ) for delivery to an expanded configuration ( FIG. 18B ) for closing the PFO.
- Proximal and distal locking components 162 , 164 may be coupled via a snap-fit mechanism for keeping patch 160 in a mushroom-like, expanded shape.
- FIG. 20 shows the mushrooming patch 160 in place within the PFO.
- a mushrooming patch 160 as just described may be delivered using a delivery catheter 168 having one or more infusion ports 169 for infusing a fluid such as saline.
- a catheter system for closing a PFO may also include a backstop member 166 for helping position the patch 160 or other closure device by engaging the left atrial wall.
- Infusion ports 169 provide enhanced visualization of the patch placement, as the infused fluid can be visualized via an external visualization device.
- delivery catheter 168 may also include one or more visualization devices such as fiber optic fibers 167 for viewing infused fluid bubbles and/or the device delivery site directly.
- FIGS. 22A and 22B show a similar patch delivery device 170 , having infusion ports 174 and a backstop 176 , but with a balloon-expandable patch 172 .
- an element of the delivery system expands in the left atrium, and serves as a backstop to help position the patch and patch delivery devices relative to the PFO.
- the backstop devices are removed after the patch has been deployed.
- Backstop devices can be balloons, wires that reform into flat coils or star-shaped elements upon deployment into the left atrium, multi-armed devices whose arms deploy radially in the left atrium and collapse back down for removal, and/or the like.
- the backstop elements are shown without the patch or other closure device for clarity.
- a balloon of low pressure elastomeric material can be attached to a catheter shaft fitted with fiber optic elements which terminate within the shaft of the catheter underneath the distal balloon.
- the catheter shaft is sized to allow passage of a backstop device similar in design and function to that previously described, e.g., for use in deployment of the sombrero/mushroom patch devices.
- a spiral channel is provided within the woven patch which allows a more rigid spiral member to be slidably fixed to the patch such that when the assembly is in a non-deployed state, such as illustrated in FIG. 22A , the spiral reinforcement member is wrapped down around the catheter shaft, balloon, and functions to hold the patch in position on the catheter during delivery of the system to the treatment site.
- the backstop or distal portion of the device is advanced across the PFO, and serves to help bring the catheter and patch assembly into a stable position within the PFO.
- the balloon is then inflated, expanding the patch to cover the PFO region with sufficient overlap to ensure full closure.
- Laser light can activate a solder (e.g., protein/dye solder) impregnated into the patch and spiral reinforcement, for example, soldering the patch into place across the PFO.
- a solder e.g., protein/dye solder
- the backstop and balloon catheter are then withdrawn, leaving only the patch in place.
- the spiral reinforcement can be any of the known bioabsorbable polymers, or a metallic or nonreabsorbable polymer.
- the reinforcement can be fitted within a sleeve formed within the patch, attached using loosely applied stitches, for example, which would still allow movement of the fiber during deployment, threaded through slits in the woven material, or any other means which allows movement of the fiber, but retain the patch in place in its final position.
- the fiber and patch can be fixed together at the distal terminus of the fiber, at about the outer of the patch, so that during balloon inflation only the proximal portion of the reinforcement moves, and is drawn distally into the patch.
- the patch can be made of non-distensible weave, such that bringing the patch down into the pre-deployment configuration shown in FIG. 22A requires folding of the patch around the balloon.
- the material is gathered around the balloon and reinforcement fiber like a curtain which is gathered together on a rod.
- the patch can be made of a distensible material, such that expansion of the balloon causes elastic deformation of the material into its final configuration.
- balloon expansion could cause a densely packed weave of the patch to become a looser weave, the change in weave density providing the required dimensional change.
- the reinforcing fiber if it is made from an absorbable material, might be of a formulation where the application of moderate heat (e.g., low enough not to cause thrombus formation in the right atrium) softens the material, assisting in deployment.
- moderate heat e.g., low enough not to cause thrombus formation in the right atrium
- the material could be formulated to reharden upon removal of the heat, helping to fix the device into its final position.
- a similar application of heat could assist in deployment of the reinforcing fiber if it were, e.g., a low-glass transition temperature non-absorbable polymer or nitinol metal fiber as well.
- FIG. 23 shows a backstop device 180 having multiple prongs 182 that are biased inferiorly to preferentially engage the septum primum without interfering with the left atrial wall.
- FIG. 24 demonstrates another embodiment of a backstop device 190 having a coil 192 , such as a shape memory coil that acts as the backstop.
- a backstop device 200 may use an expandable balloon 202 as a backstop member.
- FIG. 26 shows another backstop device 210 including a petal backstop member 212 .
- any of these embodiments may have a shape-changing mechanism to allow them to be delivered in a predominantly straight configuration, such as through a delivery catheter, and then expand or otherwise change shape to conform to the atrial side of the septum priumum and/or the septum secundum.
- Shape-changing may be accomplished by any suitable technique, such as using shape-memory materials like nitinol or spring stainless steel, inflating an expandable balloon, or the like.
- Once a backstop is in place in some embodiments its shape may be locked to maintain the shape.
- the backstop is withdrawn, typically by restoring the backstop member to the straight configuration and withdrawing it through a delivery catheter.
Abstract
Methods and apparatus for treatment of patent foramen ovale (PFO) generally involve use of a catheter having at least one closure device at its distal end. In some embodiments, the catheter also includes one or more energy transmission members for delivering energy to the closure device(s) and to the tissue adjacent the PFO to induce closure of the PFO. Closure devices may comprise, for example, a bioresorbable matrix or a non-resorbable matrix. In some embodiments, the closure device contains particles dispersed within the closure device to increase conductance and/or to reduce resistance and/or impedance. An exemplary method involves advancing a catheter to position its distal end into the tunnel of the PFO and fixing the closure device within the tunnel of the patent foramen PFO.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/665,974 (Attorney Docket No. 022128-000300US), filed Sep. 18, 2003, which claimed priority to U.S. Provisional Patent Application Nos. 60/458,854 (Attorney Docket No. 022128-000100US (formerly 20979-002100US)), filed on Mar. 27, 2003; 60/478,035 (Attorney Docket No. 022128-000110US (formerly 20979-002110US)), filed on Jun. 11, 2003, and 60/490,082 (Attorney Docket No. 022128-000120US (formerly 20979-002120US)), filed on Jul. 24, 2003, the full disclosures of which are incorporated herein by reference.
- The invention generally relates to medical apparatus and methods. More specifically, the invention relates to apparatus and methods for treatment of patent foramen ovale.
- Fetal blood circulation is much different than adult circulation. Because fetal blood is oxygenated by the placenta, rather than the fetal lungs, blood is generally shunted away from the lungs to the peripheral tissues through a number of vessels and foramens that remain patent (i.e., open) during fetal life and typically close shortly after birth. For example, fetal blood passes directly from the right atrium through the foramen ovale into the left atrium, and a portion of blood circulating through the pulmonary artery trunk passes through the ductus arteriosus to the aorta. This fetal circulation is shown in attached
FIG. 1 . - At birth, as a newborn begins breathing, blood pressure in the left atrium rises above the pressure in the right atrium. In most newborns, a flap of tissue closes the foramen ovale and heals together. In approximately 20,000 babies born each year in the US, the flap of tissue is missing, and the hole remains open as an atrial septal defect (ASD). In a much more significant percentage of the population (estimates range from 5% to 20% of the entire population), the flap is present but does not heal together. This condition is known as a patent foramen ovale (PFO). Whenever the pressure in the right atrium rises above that in the left atrium, blood pressure can push this patent channel open, allowing blood to flow from the right atrium to the left atrium.
- Patent foramen ovale has long been considered a relatively benign condition, since it typically has little effect on the body's circulation. More recently, however, it has been found that a significant number of strokes may be caused at least in part by PFO. In some cases, stroke may occur because a PFO allows blood containing small thrombi to flow directly from the venous circulation to the arterial circulation and into the brain, rather than flowing to the lungs where the thrombi can become trapped and gradually dissolved. In other cases, thrombi might form in the patent channel of the PFO itself and become dislodged when the pressures cause blood to flow from the right atrium to the left atrium. It has been estimated that patients with PFOs who have already had cryptogenic strokes have a 4% risk per year of having another stroke.
- Further research is currently being conducted into the link between PFO and stroke. At the present time, if someone with a PFO has two or more strokes, the healthcare system in the U.S. may reimburse a surgical or other interventional procedure to definitively close the PFO. It is likely, however, that a more prophylactic approach would be warranted to close PFOs to prevent the prospective occurrence of a stroke. The cost and potential side-effects and complications of such a procedure must be low, however, since the event rate due to PFOs is relatively low. In younger patients, for example, PFOs sometimes close by themselves over time without any adverse health effects.
- Another highly prevalent and debilitating condition—chronic migraine headaches—has also been linked with PFO. Although the exact link has not yet been explained, PFO closure has been shown to eliminate or significantly reduce migraine headaches in many patients. Again, prophylactic PFO closure to treat chronic migraine headaches might be warranted if a relatively non-invasive procedure were available.
- Currently available interventional therapies for PFO are generally fairly invasive and/or have potential drawbacks. One strategy is simply to close a PFO during open heart surgery for another purpose, such as heart valve surgery. This can typically be achieved via a simple procedure such as placing a stitch or two across the PFO with vascular suture. Performing open heart surgery purely to close an asymptomatic PFO or even a very small ASD, however, would be very hard to justify.
- A number of interventional devices for closing PFOs percutaneously have also been proposed and developed. Most of these devices are the same as or similar to ASD closure devices. They are typically “clamshell” or “double umbrella” shaped devices which deploy an area of biocompatible metal mesh or fabric (ePTFE or Dacron, for example) on each side of the atrial septum, held together with a central axial element, to cover the PFO. This umbrella then heals into the atrial septum, with the healing response forming a uniform layer of tissue or “pannus” over the device. Such devices have been developed, for example, by companies such as Nitinol Medical Technologies, Inc. (Boston, Mass.) and AGA Medical, Inc. (White Bear Lake, Minn.). U.S. Pat. No. 6,401,720 describes a method and apparatus for thoracoscopic intracardiac procedures which may be used for treatment of PFO.
- Although available devices may work well in some cases, they also face a number of challenges. Relatively frequent causes of complications include, for example, improper deployment, device embolization into the circulation and device breakage. In some instances, a deployed device does not heal into the septal wall completely, leaving an exposed tissue which may itself be a nidus for thrombus formation. Furthermore, currently available devices are generally complex and expensive to manufacture, making their use for prophylactic treatment of PFO impractical. Additionally, currently available devices typically close a PFO by placing material on either side of the tunnel of the PFO, compressing and opening the tunnel acutely, until blood clots on the devices and causes flow to stop. No presently known methods or devices close a PFO by inserting a device primarily into the tunnel of the PFO to cause closure.
- Research into methods and compositions for tissue welding has been underway for many years. Of particular interest are technologies developed by McNally et.al., (as shown in U.S. Pat. No. 6,391,049 and Fusion Medical (as shown in U.S. Pat. Nos. 5,156,613, 5,669,934, 5,824,015 and 5,931,165). These technologies all disclose the use of energy delivery to tissue solders and patches in order to join tissue and form anastamoses between arteries, bowel, nerves, etc. Also of interest are a number of patents by inventor Sinofsky, relating to laser suturing of biological materials (e.g., U.S. Pat. Nos. 5,725,522, 5,569,239, 5,540,677 and 5,071,417). Other references, such as PCT Patent Application Publication No. WO 03/0534493, describe devices for closing PFOs involving bioresorbable materials. While these basic technologies may be applicable to the closure of PFOs, however, none of them show methods or apparatus suitable for positioning the tissues of the PFO for welding or for delivering the energy to the site to be welded.
- Therefore, it would be advantageous to have improved methods and apparatus for treating a PFO. Ideally, such methods and apparatus would help seal the PFO while leaving only a harmless repair material, or possibly very little or no foreign material, in the body. Also ideally, such methods and apparatus would be relatively simple to manufacture and use, thus rendering prophylactic treatment of PFO, such as for stroke prevention, a viable option. It would also be advantageous to have a device which could effect closure of a PFO without requiring insertion of a catheter through the PFO. At least some of these objectives will be met by the present invention.
- Methods and apparatus for treatment of patent foramen ovale (PFO) generally involve use of a catheter having treatment apparatus at its distal end. In the present embodiments, the treatment apparatus includes at least one conductive element disposed at the distal end of the catheter. The treatment apparatus may also include a positive stop feature to limit the penetration of the treatment apparatus to a predetermined depth into the PFO. The apparatus also includes an energy source, such as a radiofrequency generator, used in conjunction with a closure device.
- Methods generally involve advancing the catheter to position its distal end near the PFO and using the treatment apparatus to secure a closure device to the tissue with energy and/or tissue solder or tissue adhesive to close the PFO. The closure device may be a plug that physically covers the PFO. Alternatively, the closure device may be a plug inserted selectively into the PFO.
- In one aspect, a method of treating a patent foramen ovale comprises: advancing a catheter device having a proximal end, a distal end and at least one conductive element and closure device near the distal end through vasculature of a patient to position the distal end adjacent the patent foramen ovale; advancing the at least one conductive element and closure device to or into the patent foramen ovale; exposing the at least one conductive element to the closure element and/or to the tissue; and applying energy to the tissue and/or closure device to fix the device to or into the tissue of the PFO. In some embodiments, advancing the catheter comprises advancing through at least one of a femoral vein, an iliac vein, an inferior vena cava, a brachial vein, an axial vein, a subclavian vein, and a superior vena cava of the patient. In some embodiments, advancing the catheter comprises advancing over a guidewire.
- In other aspects, exposing the at least one conductive element and closure device involves retracting a catheter body of the catheter to expose the at least one conductive element and closure device out of an opening in the catheter body at or near the distal end of the catheter. Alternatively, exposing the at least one conductive element and closure device may involve advancing the conductive element and closure device relative to the catheter body. In any embodiment, the at least one conductive element and closure device may be retracted and advanced as many times as desired. Optionally, any embodiment may include visualization of the PFO and/or tissue surrounding the PFO using one or more visualization devices.
- In further aspects, advancing the at least one conductive element and closure device to or into the PFO optionally includes inserting at least a portion of the at least one conductive element and closure device into the PFO until a positive stop provided on the treatment apparatus engages the peripheral limits of the PFO, limiting penetration depth of the at least one conductive element and closure device.
- A further aspect of advancing the closure device to or into the PFO includes providing a closure device made from a self-expanding bioresorbable, doped matrix and allowing the self expanding material of the closure device to fill and/or span the PFO. In alternative embodiments, a self-expanding or expandable matrix that is not bioresorbable may be used.
- In another method of therapy, advancing the treatment apparatus comprises advancing two or more conductive elements to the PFO and using the two or more conductive elements to apply lateral, dilatory or a combination of both forces to bring the tissue of the septum primum and septum secundum of the PFO into apposition. Alternatively, the lateral and/or dilatory forces may bring the tissue of the septum primum and septum secundum into apposition with one or more of the conductive elements, or into apposition with the closure device. In this method, advancing the closure device comprises spanning the area between the two or more conductive elements with the closure device. In a further aspect of the method, advancing the closure device may comprise allowing the closure device to self-expand in and/or near the PFO to fill any space left after the primum and secundum are brought into apposition by the two or more conductive elements. In some embodiments, applying lateral, dilatory or a combination of forces may be achieved by inflating a balloon within the conductive elements, or by incorporating the conductive elements into a balloon.
- Methods for fixing the closure device to the PFO include applying energy to the at least one conductive element of the treatment apparatus via the delivery catheter. In one method, monopolar radiofrequency energy is applied through the at least one conductive element and the conductively doped closure device, heating the tissue and/or closure device, to fix the closure device to the tissue and close the PFO. Alternatively, applying energy to the closure device may cause solder or adhesive-filled compartments within the closure device to rupture, fixing the closure device to the PFO.
- An alternative method includes applying bipolar radiofrequency energy between the at least one conductive element and a ground electrode on the delivery catheter or proximal treatment apparatus to heat the tissue and/or closure device to fix the closure device to the tissue and close the PFO.
- A further method entails applying bipolar radiofrequency energy between the two or more conductive elements of the treatment apparatus to heat the tissue and/or closure device to fix the closure device to the tissue and close the PFO. In some methods, the energy may be conducted from each of the two or more conductive elements of the treatment apparatus into specifically defined conductive pathways of the closure device.
- In yet another aspect, apparatus for treating PFO comprises an elongate catheter body having a proximal end and a distal end and a treatment apparatus comprised of at least one retractable conductive element movable between a retracted position wherein the conductive element resides wholly within the catheter body and a deployed position wherein at least a portion of the conductive element extends through an opening in the catheter body adjacent the distal end. In some embodiments, the catheter body is passable over a guidewire. Also in some embodiments, the at least one retractable conductive element contains at least one positive stop provided to engage the peripheral limits of the PFO, limiting penetration depth of the at least one conductive element and closure device. Optionally, the at least one retractable conductive element comprises multiple conductive elements. Also in some embodiments, the at least one retractable conductive element is movable relative to the catheter body to extend the at least one conductive element through the PFO and retract the conductive element back through the foramen ovale.
- Apparatus for treating a PFO also consist of a closure device, which may include a bioabsorbable or non-resorbable matrix. The matrix may include conductive elements to reduce impedance over the desired energy transmission plane and to enhance energy conduction from the energy delivery means to the tissue in order to more predictably and securely affix the closure device to the tissue. Optionally, the closure device may incorporate tissue solders or adhesives. These solders or adhesives may be designed to achieve full adhesion upon energy delivery. Conductive elements incorporated into the closure device may include conductive wires. Alternatively, conductive elements may comprise patterned doping of conductive particles into specific conductive shapes or pathways within the closure device. Example conductive wires may be made from gold, platinum, iridium, or alloys thereof. Example doping elements include powdered metals such as tantalum, platinum, gold, iridium, or alloys thereof. Example matrices include self expanding collagen, hyaluronic acid, absorbable sponge, matrices of bioabsorbable polymers, and bioresorbable metals, such as iron or nickel alloys. Example tissue solders or adhesives include autologous blood, albumin, collagen, fibrin, cyanoacrylates, mussel byssus adhesives, polymer hot melt adhesives or the like. Combinations of several of these solders or adhesives may also be utilized.
- Other embodiments of closure devices incorporating conductive elements may include design features such as skirts, flanges or lips which are designed to engage the tissue of the right atrium adjacent to the PFO, acting as a positive stop and as additional retention means. In some cases, the closure device will incorporate deformable non-resorbable frame members in order to facilitate closure device positioning and retention.
-
FIG. 1 is a diagram of the fetal circulation; -
FIG. 2 is a diagram of a catheter apparatus according to an embodiment of the present invention, having a conductive element and closure device, the catheter passing through the inferior vena cava and right atrium and through the patent foramen ovale; -
FIGS. 3A-3C are a diagram of a catheter apparatus according to an embodiment of the present invention, having a conductive element and closure device; -
FIG. 4 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and positive stops; -
FIGS. 5A-5D are diagrams showing the delivery of devices according to an embodiment of the present invention, wherein lateral force and expanding matrices are used to close a PFO; -
FIG. 6 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements which apply lateral and dilatory force to the PFO; -
FIGS. 7A-7C are diagrams showing the delivery of devices according to an embodiment of the present invention, wherein lateral and dilatory forces and closure devices are used to close a PFO; -
FIG. 8 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements which apply lateral and dilatory force to the PFO via balloon actuation; -
FIG. 9 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and a closure device consisting of a conductively doped matrix; -
FIG. 10 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and a conductive particle-doped closure device, wherein the conductive doping particles form specific conduction pathways; -
FIG. 11 is a diagram of a closure device according to an embodiment of the present invention, having conductive elements and bioresorbable elements; -
FIG. 12 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and a conductive particle-doped closure device wherein the conductive doping particles form specific conduction pathways which are electrically isolated from one another; -
FIG. 13 is a diagram of a catheter apparatus according to an embodiment of the present invention, having multiple conductive elements and a conductive particle-doped closure device, wherein the conductive doping particles form specific conduction pathways which are electrically isolated from one another in a multi-layer configuration; -
FIG. 14 is a diagram of a catheter apparatus according to an embodiment of the present invention, having a self-expanding, non-resorbable patch closure device; -
FIG. 15 is a diagram of a catheter apparatus according to an embodiment of the present invention, having a balloon-expandable, non-resorbable patch closure device; -
FIG. 16 is a diagram of a catheter apparatus according to an embodiment of the present invention, having non-resorbable patch members and a non-resorbable frame; -
FIG. 17A is a diagram of a catheter apparatus according to an embodiment of the present invention, in position to weld a patch to tissues to close a PFO; -
FIG. 17B is a diagram of a delivery catheter and patch according to an embodiment of the present invention; -
FIGS. 18A and 18B are diagrams of a PFO patch according to an embodiment of the present invention; -
FIG. 19 is a diagram of a locking PFO patch according to an embodiment of the present invention; -
FIG. 20 is a diagram of a PFO patch according to an embodiment of the present invention in position across a PFO; -
FIGS. 21A-21C are diagrams of a catheter apparatus according to an embodiment of the present invention, having a backstop member for positioning a patch in a PFO; -
FIGS. 22A and 22B are diagrams of a catheter apparatus according to an embodiment of the present invention, having an expandable PFO patch and a backstop member; and -
FIGS. 23-26 are diagrams of various backstop members for use in catheter apparatus according to various embodiments of the present invention. - Methods and apparatus of the invention generally provide for treating tissue adjacent a patent foramen ovale (PFO) to cause closure of the foramen. The methods and devices typically include a catheter device which can be advanced through the vasculature of a patient to position the distal end of the catheter near the PFO to provide treatment. Treatment apparatus disposed at or near the distal end of the catheter can then be used to treat at least a portion of the heart wall tissue surrounding the PFO, to cause the PFO to close. In many embodiments, the treatment apparatus is used to transmit energy to a closure device and to the tissues surrounding the PFO. The energy causes bonding to occur between the tissue of the PFO and the closure device, which may in turn induce a response in the tissues which causes the PFO to close. In one embodiment, the treatment apparatus includes one or more conductive elements. Such conductive elements may be retractable into (and extendable out of) the body of the catheter.
- In some embodiments, closure devices may be made from bioresorbable materials such as collagen, hyaluronic acids, or various formulations of bioresorbable polymers such as PLLA, PLGA, degradable metals or the like. Alternatively, closure devices may comprise one or more non-resorbable materials, such Dacron®, ePTFE, non-degradable metallic weaves such as platinum alloys, gold, nitinol or stainless steel, or composites of several of these materials. The closure device may be self expanding or expandable to fill gaps left between the tissues of the PFO after they are brought into apposition for sealing. Of particular interest are embodiments wherein conductive particles are incorporated into the matrix of the closure device to increase conductivity and inductance through the closure device and the tissues of the PFO in order to increase the efficacy and consistency of the closure. These particles may be evenly distributed throughout the matrix of the closure device, or they might be arranged into specifically designed conductive pathways.
- For the purposes of this description, the tissue surrounding, encircling or forming a PFO will generally be referred to as “tissue adjacent the PFO” or “PFO tissue” or “tissue surrounding the PFO.” A “PFO” itself is actually a foramen, or opening, in tissue of the heart wall between the left and right atria (the interatrial septum), while tissue adjacent the PFO is tissue of the septum primum and the septum secundum that has failed to fuse, thus leaving the foramen ovale patent. Many embodiments of the present invention involve apparatus and methods acting on tissue adjacent the PFO, and it should be emphasized that “tissue adjacent the PFO” means tissue of the septum primum, tissue of the septum secundum, and/or any other adjacent heart wall tissue upon which an embodiment of the invention may act.
-
FIG. 2 shows acatheter system 10 according to an embodiment of the present invention in place across a PFO, andFIGS. 3A-3C demonstrate the use of such acatheter system 10. In one embodiment,catheter system 10 consists of anouter delivery catheter 11 and ininner catheter 12 with at least onetreatment apparatus 14 and at least oneclosure device 16 disposed at its distal tip.Treatment apparatus 14 may comprise, for example, at least one conductive element for transmitting energy such as radiofrequency energy to the closure device and to the tissue of the PFO.Closure device 16 may be any of the embodiments discussed further below, such as a bioresorbable or non-resorbable matrix or patch, or any other device for closure of a PFO. - As shown in
FIGS. 3A-3C ,delivery catheter 11 is placed through or into the PFO, withinner catheter 12 havingtreatment apparatus 14 andclosure device 16 housed within it.Outer delivery catheter 11 is withdrawn to exposetreatment apparatus 14 to the tissues of the PFO. Energy is applied viatreatment apparatus 14 toclosure device 16 to causeclosure device 16 and/or tissue solders or adhesives within the matrix ofclosure device 16 to bond with the tissues of the PFO, securingclosure device 16 to the tissue. Optionally,closure device 16 may incorporate conductive or inductive particulate material in order to enhance energy transmission and tissue bonding. Once the bond is complete, energy delivery ceases and theentire delivery system 10 andtreatment apparatus 14 are withdrawn from the body, leavingclosure device 16 in place.Closure device 16 may be constructed of a sponge-like material that will self-seal upon withdrawal of the treatment apparatus fromclosure device 16. Optionally,treatment apparatus 14 might be withdrawn fromclosure device 16 as energy is being applied, sealing the track of thetreatment apparatus 14 as it is withdrawn. - Devices such as those described in
FIGS. 2 and 3 A-C will most preferably make use of monopolar radiofrequency (RF) energy transmitted from the conductive elements of the treatment apparatus, through the patient, completing the circuit to a ground pad affixed to the external skin of the patient. Control systems within the energy delivery systems may automatically stop energy delivery upon detecting a change in condition of energy delivery, for instance an increase in electrical resistance or impedance withinclosure device 16 and/or tissues, or an increased energy draw from the treatment apparatus. In other embodiments, bipolar RF energy may be transmitted from the treatment apparatus. Alternatively, other forms of energy may be applied to one or more closure devices and/or to tissues adjacent a PFO, such as but not limited to resistive heating, ultrasound, microwave or laser energy. -
FIG. 4 shows a distal end of one embodiment of acatheter 10 havingtreatment apparatus 14 comprising two conductive elements, each having an insulatedproximal portion 20, a “positive stop” 22, and an uninsulated distalenergy transmission portion 24.Catheter 10 may also include aground site 26 for bipolar use. In this embodiment, a closure device of the types described elsewhere in this disclosure may span the distance between the uninsulatedenergy transmission portions 24 of the conductive elements. Positive stops 22 engage the peripheral limits of the PFO in order to allow passage oftreatment apparatus 14 to a predetermined depth within the PFO. The multiple conductive elements may be made to separate through spring-action or through positive mechanical means in order to apply lateral forces to the PFO, stretching the tissue of the septum primum and septum secundum and bringing the edges of these tissue structures into apposition. -
FIGS. 5A-5D show the use of a device such as that described inFIG. 4 . The system is delivered to the PFO as previously described, and upon reaching the PFO a delivery sheath is withdrawn, exposing thetreatment apparatus 14 and positive stop. The lateral motion (FIG. 5B ) of thetreatment apparatus 14 and the positive stops 22 assist in bringing the closure device into position within the PFO, and in bringing the tissues of the PFO in apposition to one another. Optionally, the matrix may expand to fill any voids between the tissues of the PFO (FIG. 5C ). Energy is applied to the closure device via the conductive elements of thetreatment apparatus 14, and the delivery system and thetreatment apparatus 14 are withdrawn (FIG. 5D ). Bipolar energy may be applied between the conductive elements or between the elements and theground site 26. -
FIGS. 6 and 7 A-C show atreatment apparatus 30 having multipleconductive elements 32 which apply both lateral and dilatory force to the PFO, in order to more forcefully bring aclosure device 34 into apposition with the tissues of the PFO. In some embodiments,closure device 34, which may incorporate any of the features previously disclosed, may form a closed-ended sock-like structure. In some embodiments, the proximal edge ofclosure device 34 may be positioned onconductive elements 32 such that when lateral and dilatory forces are exerted onclosure device 34 and the tissues of the PFO, the proximal portion ofclosure device 34 forms askirt 36 which contacts the tissue of the right atrium peripheral to the PFO. In this embodiment, as shown inFIGS. 7B and 7C , energy application may cause a main portion ofclosure device 34 to adhere to the tunnel of the PFO, while the skirtedarea 36 adheres to the right atrial tissue surrounding the PFO tunnel. -
FIG. 8 shows an alternative embodiment of atreatment apparatus 40 extended distally from adelivery catheter 42. In this embodiment, aballoon 50 exerts dilatory and lateral forces on the PFO andclosure device 48. Conductiveelement retention wires 46 run throughsmall lumens 44 or channels intreatment apparatus 40 and exert lateral forces onballoon 50,closure device 48 and PFO tissues, to help flattenballoon 50 and conform more closely to the natural geometry of the PFO.Retention wires 46 also act as conductive elements for delivery of energy to the closure device and PFO. - Devices such as those described in FIGS. 4, 5A-D, 6, 7A-C and 8 may make use of monopolar radiofrequency energy, wherein energy is applied simultaneously to all conductive elements, completing the circuit through an external ground pad affixed to the skin of the patient. Alternatively, bipolar energy may be applied to all conductive elements simultaneously, and the circuit completed through a ground element incorporated elsewhere on the delivery system. Further embodiments may include applying bipolar energy between two or more conductive elements of the treatment apparatus, which are electrically isolated from one another within the delivery system.
- Control systems may be includes in various embodiments within the energy delivery systems for detecting and/or stopping energy delivery. Such a control system may automatically stop energy delivery upon detecting a change in a condition of energy delivery, for instance an increase in electrical resistance or impedance within the closure device and/or tissues, or an increased energy draw from the treatment apparatus. In some embodiments, a control system will stop energy delivery when a temperature is detected that relates to a sufficient temperature for tissue welding. Such control features may be accomplished by any suitable devices or combinations, such as by thermistors or the like.
-
FIG. 9 demonstrates another embodiment oftreatment apparatus 60 extending out of adelivery catheter 62, the latter of which includes an optionalelectrical ground 63. In this embodiment, theclosure device 68 is doped with an approximately even distribution of conductive particles 67 within a bioresorbable matrix. Conductive particles 67 may include, for example, powders of gold, platinum; steel, tantalum, tungsten, iridium, or alloys or combinations thereof. In any case, it will be desirable for the particle size to be smaller than a red blood cell (about 20 microns) so that upon resorption of the binding matrix of the closure device, individual conductive particles 67 may pass through the body for filtration and expulsion by the liver or kidneys without causing obstruction within the vascular bed. Generally, conductive particles 67 reduce impedance in the tissues adjacent the PFO and thus assist energy transmission to the tissues. -
FIG. 10 demonstrates another embodiment oftreatment apparatus 70 extending from adelivery catheter 72 having anelectrical ground 73. In this embodiment, specific patterns of dopedmaterial 76 are created on aclosure device 78 by selectively doping portions of theclosure device matrix 78. The dopedmaterial pattern 76 may be electrically conductive, or it may simply reduce the electrical resistance or impedance along which a signal might preferentially pass without actually being conductive. In the embodiment shown, at least one specific path is created which is in connection with both conductingelements 74 oftreatment apparatus 70. This embodiment will be particularly useful in a monopolar energy delivery arrangement or with bipolar energy delivery when the return path is part of the delivery system (as with ground 73). -
FIG. 11 demonstrates an alternative embodiment for an electrically conductive or reducedresistance closure device 80 wherein a woven or braided fabric is created from alternating fibers ofbioresorbable fibers 84 and electrically conductive or reducedresistance fibers 82. In this embodiment, the electrically conductive or reduced resistance/impedance fibers 82 will be metal fibers, rather than pathways created from selective doping of particles. Any electrically conductive or reduced resistance/impedance wire material will be suitable for the application, such as gold, steel, platinum, copper, a resorbable metal such as an iron or nickel alloy, or the like. This closure device can be made to work with either bipolar or monopolar energy delivery, depending on the exact scheme of coupling of theconductive fibers 82 to the conductive elements of the treatment apparatus. -
FIG. 12 shows yet another embodiment of aclosure device 90, havingattachment elements 92 for removably coupling closure device with conductive elements of treatment apparatus, one ormore insulation zones 94 and two or more selectively doped conductive or reduced resistance orimpedance pathways pathways first pathway 96 is most closely coupled with one conduction element of the treatment apparatus, and at least asecond pathway 98 is most closely coupled with another conduction element of the treatment apparatus, with one ormore insulation zones 94 disposed betweenpathways -
FIG. 13 demonstrates a variation of the multiple-pathway arrangement ofFIG. 12 . In this embodiment, aclosure device 100 includes an upperconductive layer 102 having at least afirst pathway 104, amiddle layer 106 providing insulation, and a lowerconductive layer 108 having at least asecond pathway 110. The layers are joined to form acomposite closure device 100 particularly suited for delivery of bipolar energy. Alternatively,upper layer 102 may be uniformly doped to provide conductivity or reduced resistance/impedance with a first electrode, andlower layer 108 may be uniformly doped and most closely coupled with a second electrode, withmiddle layer 106 again providing electrical isolation. - In all embodiments describing doping of a matrix to enhance energy transfer, association of a given doped pathway, whether is it highly selective to mimic a wire-like pathway or uniformly distributed to form a plate-like plane, the pathway may be made to be in true electrical connection with its intended conduction element, or it may simply be more strongly coupled with a given electrode than with a different electrode. True electrical conductivity may be established through the pathway or plane, or the mechanism of increased energy transfer may be that of reducing the impedance of a given path which it is desired for the energy to follow.
- As is mentioned above, closure devices of the present invention may be entirely bioresorbable, partially bioresorbable, or entirely non-resorbable. Many of the embodiments described above are intended to be bioresporbable but may also be constructed from non-resorbable materials. The descriptions that follow often focus on “patches” for closing a PFO. Typically, these patches will be non-resorbable, but again, bioresorbable or partially resorbable patches are contemplated. Furthermore, a “patch” may comprise any of a number of different closure devices, and therefore, the term patch should not be interpreted to limit the scope of the invention to any one embodiment or configuration. For the purposes of this application, “patch”, “closure device” and the like may be used interchangeably to mean any device for closing a PFO.
- That being said,
FIGS. 14, 15 and 16 illustrate apparatus and methods for welding patches using variations of normally-closed devices that are inserted into the PFO, expanded to provide secure contact to both sides of the PFO, and welded into place using energy. The device is then allowed to collapse back to its unexpanded state, sealing the PFO. Optionally, the device may be actively closed through a mechanical locking mechanism built into the device. Energy can be RF, ultrasound, microwave, resistive heating, laser, or any source that causes the device to become irreversibly adhered to the walls of the PFO. These devices may be made from a degradable metal or metal/fabric combination, so that after facilitating healing and permanent closure for the PFO, the device degrades and disappears. The devices optionally include a non-degradable fabric patch or fitted covering which heals into the surrounding tissue prior to degradation, and serves as a permanent reinforcement and an emboli containment mechanism to prevent embolism in the event that the device erode unevenly. Implantation of such self-closing devices can be facilitated by the introduction of protein solders during the welding step to facilitate adhesion and closure. In the case where laser energy is used in conjunction with protein solder, it may be desirable to mix a dye such as indocyanine green into the solder to help increase the specificity of the laser activation to the solder site. -
FIG. 14 shows deployment of a self-expandingpatch 126 from acatheter device 120 having adelivery catheter 121, aninner catheter 122 andtreatment apparatus 124 includingpatch 126 and a conductive element 125.Patch 126 expands upon being exposed fromdelivery catheter 121 and is welded, using conductive element 125 to tissue adjacent the PFO to close the PFO.FIG. 15 shows asimilar catheter device 130, having anouter catheter 131, aninner catheter 132, andtreatment apparatus 134 including a balloonexpandable patch 136, aconductive element 135 and aninflatable balloon 138. Here,patch 136 is expanded into place viaballoon 138 and then welded to PFO tissues to close the PFO.FIG. 16 shows another embodiment of a catheter device 140, this embodiment including anouter catheter 141, aninner catheter 142, one ormore patches 146 and areinforcement member 148 for helping to holdpatches 146 in place within the PFO. -
FIGS. 17-22 illustrate devices which cover the slit-like opening of the PFO like a bike tire patch, bridging from the septum primum to the septum secundum to effect the seal. Embodiments include expanding fork-like devices, braided devices which are compressed into disciform patches, and balloon expanded patches. They can be made from traditional graft and patch materials such as Dacron® or ePTFE, from non-degradable metallic weaves such as platinum alloys, gold, nitinol or stainless steel, degradable metallic weaves such as iron or magnesium alloys, degradable polymers such as PLLA, or composites of several of these materials. Adherence can be facilitated by the active introduction during welding or prior impregnation of protein solders into the devices. All energy modalities described above can be used. These devices generally employ a second catheter element which is deployed through the PFO into the left atrium. -
FIGS. 17A and 17B show right atrial cutaway and septum cross-sectional views, respectively, of one embodiment of a tissue-welded patch device for sealing a PFO. In this embodiment, apatch 150 includes conductingfibers 156 for conducting energy and acovering mesh 154 coupled withfibers 156.Patch 150 is generally delivered by advancing through adelivery catheter 152 via anintroducer rod 151. Conductingfibers 156 are coupled to an electrolytic joint 158 for transmission of energy to the wires. Upon delivery and placement, a portion ofpatch 150 tucks into the overlap of the septum secundum and the septum primum. -
FIGS. 18A, 18B , 19 and 20 show amushrooming patch 160 for closing a PFO.Patch 160 includes aproximal locking component 162 and adistal locking component 164 for enablingpatch 160 to change from a straight configuration (FIG. 18A ) for delivery to an expanded configuration (FIG. 18B ) for closing the PFO. Proximal anddistal locking components patch 160 in a mushroom-like, expanded shape.FIG. 20 shows themushrooming patch 160 in place within the PFO. - With reference now to
FIGS. 21A-21C , amushrooming patch 160 as just described may be delivered using adelivery catheter 168 having one ormore infusion ports 169 for infusing a fluid such as saline. As will be described further below, a catheter system for closing a PFO may also include abackstop member 166 for helping position thepatch 160 or other closure device by engaging the left atrial wall.Infusion ports 169 provide enhanced visualization of the patch placement, as the infused fluid can be visualized via an external visualization device. Alternatively,delivery catheter 168 may also include one or more visualization devices such asfiber optic fibers 167 for viewing infused fluid bubbles and/or the device delivery site directly.FIGS. 22A and 22B show a similarpatch delivery device 170, havinginfusion ports 174 and abackstop 176, but with a balloon-expandable patch 172. - Referring now to
FIGS. 22-26 , in some embodiments an element of the delivery system expands in the left atrium, and serves as a backstop to help position the patch and patch delivery devices relative to the PFO. The backstop devices are removed after the patch has been deployed. Backstop devices can be balloons, wires that reform into flat coils or star-shaped elements upon deployment into the left atrium, multi-armed devices whose arms deploy radially in the left atrium and collapse back down for removal, and/or the like. InFIGS. 22-26 , the backstop elements are shown without the patch or other closure device for clarity. - Referring to
FIGS. 22A and 22B , in one embodiment, a balloon of low pressure elastomeric material can be attached to a catheter shaft fitted with fiber optic elements which terminate within the shaft of the catheter underneath the distal balloon. The catheter shaft is sized to allow passage of a backstop device similar in design and function to that previously described, e.g., for use in deployment of the sombrero/mushroom patch devices. - In one exemplary embodiment, a spiral channel is provided within the woven patch which allows a more rigid spiral member to be slidably fixed to the patch such that when the assembly is in a non-deployed state, such as illustrated in
FIG. 22A , the spiral reinforcement member is wrapped down around the catheter shaft, balloon, and functions to hold the patch in position on the catheter during delivery of the system to the treatment site. Once in place in the right atrium, the backstop or distal portion of the device is advanced across the PFO, and serves to help bring the catheter and patch assembly into a stable position within the PFO. The balloon is then inflated, expanding the patch to cover the PFO region with sufficient overlap to ensure full closure. Laser light can activate a solder (e.g., protein/dye solder) impregnated into the patch and spiral reinforcement, for example, soldering the patch into place across the PFO. The backstop and balloon catheter are then withdrawn, leaving only the patch in place. - The spiral reinforcement can be any of the known bioabsorbable polymers, or a metallic or nonreabsorbable polymer. The reinforcement can be fitted within a sleeve formed within the patch, attached using loosely applied stitches, for example, which would still allow movement of the fiber during deployment, threaded through slits in the woven material, or any other means which allows movement of the fiber, but retain the patch in place in its final position. The fiber and patch can be fixed together at the distal terminus of the fiber, at about the outer of the patch, so that during balloon inflation only the proximal portion of the reinforcement moves, and is drawn distally into the patch.
- In one embodiment, the patch can be made of non-distensible weave, such that bringing the patch down into the pre-deployment configuration shown in
FIG. 22A requires folding of the patch around the balloon. In this case, the material is gathered around the balloon and reinforcement fiber like a curtain which is gathered together on a rod. In another embodiment, the patch can be made of a distensible material, such that expansion of the balloon causes elastic deformation of the material into its final configuration. In yet another embodiment, balloon expansion could cause a densely packed weave of the patch to become a looser weave, the change in weave density providing the required dimensional change. - The reinforcing fiber, if it is made from an absorbable material, might be of a formulation where the application of moderate heat (e.g., low enough not to cause thrombus formation in the right atrium) softens the material, assisting in deployment. The material could be formulated to reharden upon removal of the heat, helping to fix the device into its final position. A similar application of heat could assist in deployment of the reinforcing fiber if it were, e.g., a low-glass transition temperature non-absorbable polymer or nitinol metal fiber as well.
-
FIG. 23 shows abackstop device 180 havingmultiple prongs 182 that are biased inferiorly to preferentially engage the septum primum without interfering with the left atrial wall.FIG. 24 demonstrates another embodiment of abackstop device 190 having acoil 192, such as a shape memory coil that acts as the backstop. In another embodiment, as shown inFIG. 25 , abackstop device 200 may use anexpandable balloon 202 as a backstop member.FIG. 26 shows anotherbackstop device 210 including apetal backstop member 212. Any of these embodiments may have a shape-changing mechanism to allow them to be delivered in a predominantly straight configuration, such as through a delivery catheter, and then expand or otherwise change shape to conform to the atrial side of the septum priumum and/or the septum secundum. Shape-changing may be accomplished by any suitable technique, such as using shape-memory materials like nitinol or spring stainless steel, inflating an expandable balloon, or the like. Once a backstop is in place, in some embodiments its shape may be locked to maintain the shape. When the patch or other closure device has been delivered to the PFO, the backstop is withdrawn, typically by restoring the backstop member to the straight configuration and withdrawing it through a delivery catheter. - Although the foregoing description is complete and accurate, it has described only a few embodiments of the invention. Various changes, additions, deletions and the like may be made to one or more embodiments of the invention without departing from the scope of the invention. Additionally, different elements of the invention could be combined to achieve any of the effects described above. Thus, the description above is provided for exemplary purposes only and should not be interpreted to limit the scope of the invention as set forth in the following claims.
Claims (71)
1. A system for percutaneous transluminal closure of a cardiac opening, comprising:
a balloon for application of an adhesive comprising an outer surface, the balloon transitionable between a deflated state and an inflated state;
a catheter comprising a length between a proximal end and a distal end, wherein said balloon is joined to the distal end of the catheter; and
a first locator joined to said catheter, wherein said locator positions said balloon in said cardiac opening.
2. The system of claim 1 , wherein the first locator comprises a disk, a plurality of arms, a rod, a locator balloon, a right atrial locator, or a left atrial locator.
3. The system of claim 1 further comprising a second locator coupled to at least one of the catheter and the balloon, the second locator for positioning the closure device in the cardiac opening.
4. The system of claim 1 further comprising a second locator.
5. The system of claim 1 further comprising an adhesive coated on the first locator, or the second locator, or both the first and second locators.
6. The system of claim 1 , wherein the adhesive comprises a cyanoacrylate, a fibrin based adhesive, an albumin adhesive, a light activated adhesive, an irritant, or a tissue growth stimulator.
7. The system of claim 1 further comprising a light source coupled to the catheter for activating a light activated adhesive.
8. The system of claim 1 , wherein the balloon is tubular-shaped.
9. The system of claim 1 , wherein the adhesive is disposed on a surface of the balloon.
10. The system of claim 9 , wherein the surface of the balloon is involuted.
11. The system of claim 1 , wherein the first locator is attached to the balloon.
12. A system for percutaneous transvascular closure of an intra-cardiac opening in a patient, comprising:
a catheter comprising a distal end;
a patch defining at least one hollow channel, said patch sized and shaped for percutaneous transvascular delivery to an intracardiac anatomical site and releasably joined to the distal end of the catheter; and
an adhesive for adhering said patch over said intracardiac opening.
13. The system of claim 12 , wherein the patch comprises a bioresorbable material, or collagen.
14. The system of claim 12 , wherein the adhesive comprises a light activated adhesive.
15. The system of claim 12 , wherein the hollow channel comprises a conduit for light.
16. The system of claim 12 further comprising a frame enclosed within the hollow channel.
17. The system of claim 12 , further comprising a housing.
18. The system of claim 17 further comprising a light source.
19. The system of claim 18 , wherein the light source comprises a light-conducting medium.
20. The system of claim 19 , wherein the light source comprises a fiber optic cable.
21. The system of claim 12 further comprising a frame wherein at least a portion of the frame is positioned within the hollow channel.
22. The system of claim 21 , wherein the frame comprises a shape memory alloy.
23. A method for percutaneous transvascular closure of a cardiac opening in patient, comprising:
providing the system of claim 12 , and
positioning the patch over the cardiac opening.
24. The method of claim 23 , wherein positioning the patch over the cardiac opening comprises adhering the patch to a tissue surface of the patient proximate the cardiac opening.
25. The method of claim 23 , wherein adhering the patch to the tissue surface comprises providing light to the hollow channel defined by the patch and activating the adhesive coated on the patch with the provided light.
26. The method of claim 25 , wherein adhering the patch to the tissue surface further comprises applying a primer to the tissue surface.
27. The system of claim 21 , wherein the frame is capable of transporting radio frequency energy for application to the patch.
28. The system of claim 21 , wherein the frame is removable.
29. The system of claim 12 , further comprising means for applying radio frequency energy and an adhesive to the patch.
30. The system of claim 12 , wherein the adhesive is extrudable into the at least one hollow channel.
31. A closure device for percutaneous transvascular closure of an intra-cardiac opening in a patient, comprising:
a patch sized and shaped for percutaneous transvascular delivery to an intracardiac anatomical site;
an adhesive coated on the patch; and
at least one hollow channel enclosed within the patch.
32. A closure device for percutaneous transluminal closure of a cardiac opening, comprising:
a housing;
a releasable patch coupled to the housing; and
an adhesive coated on the releasable patch.
33. A closure device for percutaneous transluminal closure of a cardiac opening, comprising:
a patch;
at least one hollow channel enclosed within the patch; and
a removable frame enclosed within the hollow channel.
34. The closure device of claim 33 , wherein the frame comprises a shape memory alloy.
35. The closure device of claim 34 , wherein the shape memory alloy comprises nitinol.
36. A method for percutaneous transluminal closure of a cardiac opening in a patient, comprising:
inserting the closure device of claim 31 into a heart of the patient; and
positioning the closure device across the cardiac opening to substantially occlude the cardiac opening.
37. The method of claim 36 , wherein positioning the closure device across the cardiac opening comprises coupling the closure device to a tissue surface of the patient proximate the cardiac opening.
38. The method of claim 37 , wherein coupling the closure device to the tissue surface comprises providing light to the hollow channel enclosed within the patch and activating the adhesive coated on the patch with the provided light.
39. The method of claim 36 , wherein the cardiac opening is a patent foramen ovale.
40. A method for percutaneous transluminal closure of a cardiac opening in a patient, comprising:
inserting the closure device of claim 32 into a heart of the patient; and
positioning the releasable patch across the cardiac opening to substantially occlude the cardiac opening.
41. The method of claim 40 , wherein positioning the releasable patch across the cardiac opening comprises coupling the releasable patch to a tissue surface of the patient proximate the cardiac opening.
42. The method of claim 41 , wherein coupling the releasable patch to the tissue surface comprises providing a light source emitting light within the housing and activating the adhesive coated on the releasable patch with the emitted light.
43. A method for percutaneous transluminal closure of a cardiac opening in a patient, comprising:
inserting the closure device of claim 33 into a heart of the patient; and
positioning the closure device across the cardiac opening to substantially occlude the cardiac opening.
44. The method of claim 43 , wherein positioning the closure device across the cardiac opening comprises coupling the closure device to a tissue surface of the patient proximate the cardiac opening.
45. The method of claim 44 , wherein coupling the closure device to the tissue surface comprises thermally welding the closure device to the tissue surface.
46. The method of claim 45 , further comprising removing the frame of the closure device from within the hollow channel after having thermally welded the closure device to the tissue surface.
47. A method for percutaneous transluminal closure of a cardiac opening in a patient, comprising:
providing a compound, comprising:
an adhesive; and
a plurality of composite particles disposed within the adhesive, wherein the composite particles are capable of expansion upon contact with at least one of blood and water; and
injecting the compound into the cardiac opening to substantially occlude the cardiac opening.
48. The method of claim 47 , further comprising positioning a patch across an end of the cardiac opening.
49. The method of claim 47 , further comprising positioning a barrier across an end of the cardiac opening.
50. A closure device for percutaneous transluminal closure of a cardiac opening, comprising:
a balloon comprising an outer surface;
a porous band comprising a plurality of openings, the porous band encircling only a portion of the outer surface of the balloon; and
an adhesive disposed between the outer surface of the balloon and the porous band.
51. The device of claim 50 , wherein the porous band encircles a center portion of the balloon.
52. The device of claim 50 further comprising a substance for stimulating tissue growth, wherein the substance is selected from the group consisting of a growth factor, a pharmacological agent for stimulating tissue growth, an irritant for encouraging an inflammatory response, a cell, and a gene.
53. A method for percutaneous transluminal closure of a cardiac opening in a patient, comprising:
inserting the closure device of claim 50 into a heart of the patient;
positioning the closure device within the cardiac opening; and
applying a pressure to the balloon of the closure device to expose the adhesive through the plurality of openings of the porous band to the cardiac opening.
54. The method of claim 53 further comprising removing the balloon and the porous band of the closure device from the patient after the adhesive is exposed through the plurality of openings of the porous band to the cardiac opening.
55. A percutaneous transluminal system for closing a cardiac opening, comprising:
a first catheter comprising a proximal end, a distal end, and a lumen extending from the proximal end to the distal end;
a second catheter at least partially enclosed within the lumen of the first catheter, the second catheter movable between a retracted state and a deployed state; and
a lining coupled to the first and second catheters, wherein in the retracted state of the second catheter the lining is positioned within the lumen of the first catheter, and wherein in the deployed state of the second catheter the lining inverts and is positioned outside the lumen of the first catheter.
56. The system of claim 55 further comprising an adhesive coated on a surface of the lining or contained within the lining.
57. A method for percutaneous transluminal closure of a cardiac opening in a patient, comprising:
inserting, into a heart of the patient, the system of claim 55;
positioning the system proximate the cardiac opening with the second catheter in the retracted state; and
deploying the second catheter to invert the lining and position the lining within the cardiac opening.
58. The method of claim 57 , wherein the system further comprises an adhesive.
59. The method of claim 58 further comprising removing the system from the patient after the adhesive is exposed to the cardiac opening.
60. A percutaneous transluminal system for positioning a closure device in a cardiac opening, comprising:
a catheter;
a closure device coupled to the catheter; and
a first locator coupled to at least one of the catheter and the closure device, the first locator for positioning the closure device in the cardiac opening.
61. The system of claim 60 further comprising a second locator coupled to at least one of the catheter and the closure device, the second locator for positioning the closure device in the cardiac opening.
62. The system of claim 60 further comprising an adhesive.
63. The system of claim 62 further comprising a light source coupled to the catheter for activating a light activated adhesive.
64. A closure device for percutaneous transluminal closure of a cardiac opening, comprising:
a balloon comprising an outer surface;
a first adhesive coated on the outer surface of the balloon; and
a light source located within the balloon.
65. The system of claim 64 , further comprising a second adhesive.
66. The device of claim 65 , wherein at least one of the first adhesive and the second adhesive comprises a light activated adhesive.
67. A method for delivering a closure device to a cardiac opening in a patient, comprising:
inserting, into a heart of the patient, a system for positioning the closure device within the cardiac opening, the system comprising:
a catheter;
a closure device coupled to the catheter; and
a first locator coupled to at least one of the catheter and the closure device, the first locator for positioning the closure device within the cardiac opening;
using the first locator to locate the cardiac opening; and
using the first locator to position the closure device within the cardiac opening.
68. The method of claim 67 further comprising coupling the closure device to the cardiac opening to substantially occlude the cardiac opening.
69. The method of claim 67 further comprising coupling the first locator to a tissue surface of the patient proximate the cardiac opening.
70. The method of claim 67 , wherein the cardiac opening is a patent foramen ovale.
71. A method for percutaneous transluminal closure of a cardiac opening in a patient, comprising:
inserting the closure device of claim 64 into a heart of the patient;
positioning the closure device within the cardiac opening; and
coupling the closure device to the cardiac opening to substantially occlude the cardiac opening.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/506,232 US20070044811A1 (en) | 2003-03-27 | 2006-08-17 | Energy based devices and methods for treatment of patent foramen ovale |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45885403P | 2003-03-27 | 2003-03-27 | |
US47803503P | 2003-06-11 | 2003-06-11 | |
US49008203P | 2003-07-24 | 2003-07-24 | |
US10/665,974 US7165552B2 (en) | 2003-03-27 | 2003-09-18 | Methods and apparatus for treatment of patent foramen ovale |
US11/506,232 US20070044811A1 (en) | 2003-03-27 | 2006-08-17 | Energy based devices and methods for treatment of patent foramen ovale |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/665,974 Continuation US7165552B2 (en) | 2003-03-27 | 2003-09-18 | Methods and apparatus for treatment of patent foramen ovale |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070044811A1 true US20070044811A1 (en) | 2007-03-01 |
Family
ID=33136184
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/665,974 Active 2024-07-03 US7165552B2 (en) | 2003-03-27 | 2003-09-18 | Methods and apparatus for treatment of patent foramen ovale |
US11/464,746 Active 2027-07-26 US8057469B2 (en) | 2003-03-27 | 2006-08-15 | Methods and apparatus for treatment of patent foramen ovale |
US11/506,232 Abandoned US20070044811A1 (en) | 2003-03-27 | 2006-08-17 | Energy based devices and methods for treatment of patent foramen ovale |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/665,974 Active 2024-07-03 US7165552B2 (en) | 2003-03-27 | 2003-09-18 | Methods and apparatus for treatment of patent foramen ovale |
US11/464,746 Active 2027-07-26 US8057469B2 (en) | 2003-03-27 | 2006-08-15 | Methods and apparatus for treatment of patent foramen ovale |
Country Status (6)
Country | Link |
---|---|
US (3) | US7165552B2 (en) |
EP (1) | EP1605851A4 (en) |
JP (1) | JP4318718B2 (en) |
AU (1) | AU2004226398B2 (en) |
CA (1) | CA2519558A1 (en) |
WO (1) | WO2004086951A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060009799A1 (en) * | 2003-05-19 | 2006-01-12 | Kleshinski Stephen J | Embolic filtering method and apparatus |
US20070055333A1 (en) * | 2005-09-06 | 2007-03-08 | Sean Forde | Removable intracardiac RF device |
US20080009859A1 (en) * | 2003-02-13 | 2008-01-10 | Coaptus Medical Corporation | Transseptal left atrial access and septal closure |
US20080033421A1 (en) * | 2006-05-30 | 2008-02-07 | Coherex Medical, Inc. | Methods, systems, and devices for closing a patent foramen ovale using mechanical structures |
US20080033425A1 (en) * | 2006-05-30 | 2008-02-07 | Coherex Medical, Inc. | Methods, systems, and devices for sensing, measuring, and controlling closure of a patent foramen ovale |
US20080045937A1 (en) * | 2006-02-06 | 2008-02-21 | Whisenant Brian K | Patent foramen ovale closure device and methods for determining rf dose for patent foramen ovale closure |
US20080215085A1 (en) * | 2005-09-26 | 2008-09-04 | Whisenant Brian K | Compliant Electrode for Patent Foramen Ovale Closure Device |
US20090005776A1 (en) * | 2007-06-25 | 2009-01-01 | Terumo Kabushiki Kaisha | Medical device |
US20090069810A1 (en) * | 2007-08-28 | 2009-03-12 | Terumo Kabushiki Kaisha | Biological tissue closing device |
US20090069809A1 (en) * | 2007-08-28 | 2009-03-12 | Terumo Kabushiki Kaisha | Pfo closing device |
US20090076525A1 (en) * | 2007-08-28 | 2009-03-19 | Terumo Kabushiki Kaisha | Pfo closing device |
US8172839B2 (en) | 2006-02-24 | 2012-05-08 | Terumo Kabushiki Kaisha | PFO closing device |
US8394090B2 (en) | 2007-06-25 | 2013-03-12 | Terumo Kabushiki Kaisha | Medical device |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094363A2 (en) * | 2001-05-21 | 2002-11-28 | Medtronic,Inc. | Trans-septal catheter with retention mechanism |
US7338514B2 (en) | 2001-06-01 | 2008-03-04 | St. Jude Medical, Cardiology Division, Inc. | Closure devices, related delivery methods and tools, and related methods of use |
US20090054912A1 (en) * | 2001-09-06 | 2009-02-26 | Heanue Taylor A | Systems and Methods for Treating Septal Defects |
US6702835B2 (en) * | 2001-09-07 | 2004-03-09 | Core Medical, Inc. | Needle apparatus for closing septal defects and methods for using such apparatus |
US20050267495A1 (en) * | 2004-05-17 | 2005-12-01 | Gateway Medical, Inc. | Systems and methods for closing internal tissue defects |
US20070129755A1 (en) * | 2005-12-05 | 2007-06-07 | Ovalis, Inc. | Clip-based systems and methods for treating septal defects |
US20070112358A1 (en) * | 2001-09-06 | 2007-05-17 | Ryan Abbott | Systems and Methods for Treating Septal Defects |
US20080015633A1 (en) * | 2001-09-06 | 2008-01-17 | Ryan Abbott | Systems and Methods for Treating Septal Defects |
US20060052821A1 (en) * | 2001-09-06 | 2006-03-09 | Ovalis, Inc. | Systems and methods for treating septal defects |
US6776784B2 (en) * | 2001-09-06 | 2004-08-17 | Core Medical, Inc. | Clip apparatus for closing septal defects and methods of use |
US8614768B2 (en) * | 2002-03-18 | 2013-12-24 | Raytheon Company | Miniaturized imaging device including GRIN lens optically coupled to SSID |
US7976564B2 (en) * | 2002-05-06 | 2011-07-12 | St. Jude Medical, Cardiology Division, Inc. | PFO closure devices and related methods of use |
CA2499753A1 (en) * | 2002-09-23 | 2004-04-01 | Nmt Medical, Inc. | Septal puncture device |
US7257450B2 (en) * | 2003-02-13 | 2007-08-14 | Coaptus Medical Corporation | Systems and methods for securing cardiovascular tissue |
US7658747B2 (en) * | 2003-03-12 | 2010-02-09 | Nmt Medical, Inc. | Medical device for manipulation of a medical implant |
US6939348B2 (en) * | 2003-03-27 | 2005-09-06 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US7186251B2 (en) | 2003-03-27 | 2007-03-06 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US7165552B2 (en) * | 2003-03-27 | 2007-01-23 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US8021362B2 (en) * | 2003-03-27 | 2011-09-20 | Terumo Kabushiki Kaisha | Methods and apparatus for closing a layered tissue defect |
US7972330B2 (en) | 2003-03-27 | 2011-07-05 | Terumo Kabushiki Kaisha | Methods and apparatus for closing a layered tissue defect |
EP2455037A1 (en) * | 2003-03-27 | 2012-05-23 | Terumo Kabushiki Kaisha | Methods and apparatus for treatment of patent foramen ovale |
US7293562B2 (en) | 2003-03-27 | 2007-11-13 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US8372112B2 (en) * | 2003-04-11 | 2013-02-12 | St. Jude Medical, Cardiology Division, Inc. | Closure devices, related delivery methods, and related methods of use |
US20040267306A1 (en) | 2003-04-11 | 2004-12-30 | Velocimed, L.L.C. | Closure devices, related delivery methods, and related methods of use |
US7311701B2 (en) * | 2003-06-10 | 2007-12-25 | Cierra, Inc. | Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound |
US9861346B2 (en) | 2003-07-14 | 2018-01-09 | W. L. Gore & Associates, Inc. | Patent foramen ovale (PFO) closure device with linearly elongating petals |
US8480706B2 (en) | 2003-07-14 | 2013-07-09 | W.L. Gore & Associates, Inc. | Tubular patent foramen ovale (PFO) closure device with catch system |
ES2436596T3 (en) | 2003-07-14 | 2014-01-03 | W.L. Gore & Associates, Inc. | Oval foramen tubular permeable closure device (FOP) with retention system |
WO2005034763A1 (en) * | 2003-09-11 | 2005-04-21 | Nmt Medical, Inc. | Devices, systems, and methods for suturing tissue |
US20050113719A1 (en) | 2003-09-26 | 2005-05-26 | Vahid Saadat | Left atrial access apparatus and methods |
US20050125032A1 (en) * | 2003-10-10 | 2005-06-09 | Whisenant Brian K. | Patent foramen ovale (PFO) closure devices, delivery apparatus and related methods and systems |
US20050192627A1 (en) * | 2003-10-10 | 2005-09-01 | Whisenant Brian K. | Patent foramen ovale closure devices, delivery apparatus and related methods and systems |
EP1867287B8 (en) * | 2003-10-24 | 2011-10-05 | Tyco Healthcare Group LP | Patent foramen ovale closure system |
WO2005046487A1 (en) | 2003-11-06 | 2005-05-26 | Nmt Medical, Inc. | Transseptal puncture apparatus |
US8292910B2 (en) | 2003-11-06 | 2012-10-23 | Pressure Products Medical Supplies, Inc. | Transseptal puncture apparatus |
US20050192626A1 (en) * | 2004-01-30 | 2005-09-01 | Nmt Medical, Inc. | Devices, systems, and methods for closure of cardiac openings |
WO2005074517A2 (en) * | 2004-01-30 | 2005-08-18 | Nmt Medical, Inc. | Welding systems for closure of cardiac openings |
JP2007535997A (en) | 2004-05-07 | 2007-12-13 | エヌエムティー メディカル, インコーポレイティッド | Capturing mechanism of tubular septal occluder |
US7704268B2 (en) * | 2004-05-07 | 2010-04-27 | Nmt Medical, Inc. | Closure device with hinges |
US7367975B2 (en) * | 2004-06-21 | 2008-05-06 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US7678133B2 (en) * | 2004-07-10 | 2010-03-16 | Arstasis, Inc. | Biological tissue closure device and method |
US7473252B2 (en) * | 2004-10-07 | 2009-01-06 | Coaptus Medical Corporation | Systems and methods for shrinking and/or securing cardiovascular tissue |
JP5033787B2 (en) * | 2005-04-11 | 2012-09-26 | テルモ株式会社 | Method and apparatus for effecting closure of a lamellar tissue defect |
CA2605538A1 (en) * | 2005-04-28 | 2006-11-02 | Nmt Medical, Inc. | System and method for bonding closure of an intra-cardiac opening using energy |
US20070042326A1 (en) * | 2005-06-01 | 2007-02-22 | Osseous Technologies Of America | Collagen antral membrane expander |
US8579936B2 (en) | 2005-07-05 | 2013-11-12 | ProMed, Inc. | Centering of delivery devices with respect to a septal defect |
US7824397B2 (en) * | 2005-08-19 | 2010-11-02 | Boston Scientific Scimed, Inc. | Occlusion apparatus |
US7998095B2 (en) * | 2005-08-19 | 2011-08-16 | Boston Scientific Scimed, Inc. | Occlusion device |
US7837619B2 (en) * | 2005-08-19 | 2010-11-23 | Boston Scientific Scimed, Inc. | Transeptal apparatus, system, and method |
US7766906B2 (en) * | 2005-08-19 | 2010-08-03 | Boston Scientific Scimed, Inc. | Occlusion apparatus |
US8062309B2 (en) * | 2005-08-19 | 2011-11-22 | Boston Scientific Scimed, Inc. | Defect occlusion apparatus, system, and method |
US7846179B2 (en) * | 2005-09-01 | 2010-12-07 | Ovalis, Inc. | Suture-based systems and methods for treating septal defects |
WO2007030486A1 (en) * | 2005-09-06 | 2007-03-15 | Nmt Medical, Inc. | In tunnel electrode for sealing intracardiac defects |
US9259267B2 (en) | 2005-09-06 | 2016-02-16 | W.L. Gore & Associates, Inc. | Devices and methods for treating cardiac tissue |
WO2007035726A2 (en) * | 2005-09-19 | 2007-03-29 | Mayo Foundation For Medical Education And Research | Implantable closure apparatus and methods |
US20070088388A1 (en) * | 2005-09-19 | 2007-04-19 | Opolski Steven W | Delivery device for implant with dual attachment sites |
US20070106214A1 (en) * | 2005-10-17 | 2007-05-10 | Coaptus Medical Corporation | Systems and methods for securing cardiovascular tissue, including via asymmetric inflatable members |
WO2007055783A1 (en) * | 2005-11-08 | 2007-05-18 | Nmt Medical, Inc. | Conformable electrode catheter and method of use |
US20070244494A1 (en) * | 2006-04-18 | 2007-10-18 | Downing Stephen W | Methods and devices for treating atrial septal defects |
CA2654767C (en) * | 2006-06-09 | 2014-12-23 | Daniel Olsen | Single disc intraluminal patent foramen ovale closure device |
US20100069849A1 (en) * | 2006-06-30 | 2010-03-18 | Kassab Ghassan S | Percutaneous intravascular access to cardiac tissue |
US20080039743A1 (en) * | 2006-08-09 | 2008-02-14 | Coherex Medical, Inc. | Methods for determining characteristics of an internal tissue opening |
US8529597B2 (en) | 2006-08-09 | 2013-09-10 | Coherex Medical, Inc. | Devices for reducing the size of an internal tissue opening |
US9220487B2 (en) | 2006-08-09 | 2015-12-29 | Coherex Medical, Inc. | Devices for reducing the size of an internal tissue opening |
US20080051830A1 (en) * | 2006-08-24 | 2008-02-28 | Boston Scientific Scimed, Inc. | Occluding device and method |
US20080065156A1 (en) | 2006-09-08 | 2008-03-13 | Hauser David L | Expandable clip for tissue repair |
US20080161825A1 (en) * | 2006-11-20 | 2008-07-03 | Stout Medical Group, L.P. | Anatomical measurement tool |
US20080140113A1 (en) * | 2006-12-07 | 2008-06-12 | Cierra, Inc. | Method for sealing a pfo using an energy delivery device |
WO2008094706A2 (en) * | 2007-02-01 | 2008-08-07 | Cook Incorporated | Closure device and method of closing a bodily opening |
US8617205B2 (en) | 2007-02-01 | 2013-12-31 | Cook Medical Technologies Llc | Closure device |
EP2117441A1 (en) * | 2007-02-05 | 2009-11-18 | Boston Scientific Scimed, Inc. | Apparatus and method for closing an opening in a blood vessel using a permanent implant |
WO2008124603A1 (en) | 2007-04-05 | 2008-10-16 | Nmt Medical, Inc. | Septal closure device with centering mechanism |
US7835074B2 (en) | 2007-06-05 | 2010-11-16 | Sterling Lc | Mini-scope for multi-directional imaging |
US8292907B2 (en) * | 2007-08-31 | 2012-10-23 | Cook Medical Technologies Llc | Balloon assisted occlusion device |
US20090062839A1 (en) * | 2007-08-31 | 2009-03-05 | Cook Incorporated | Barbed stent vascular occlusion device |
US7875054B2 (en) * | 2007-10-01 | 2011-01-25 | Boston Scientific Scimed, Inc. | Connective tissue closure device and method |
EP2205309A4 (en) * | 2007-10-05 | 2011-05-11 | Coaptus Medical Corp | Systems and methods for transeptal cardiac procedures |
JP2011502587A (en) * | 2007-11-07 | 2011-01-27 | オバリス, インコーポレイテッド | System, apparatus and method for transverse orientation in septal defect treatment |
US20130165967A1 (en) | 2008-03-07 | 2013-06-27 | W.L. Gore & Associates, Inc. | Heart occlusion devices |
US20090287048A1 (en) * | 2008-05-16 | 2009-11-19 | Sterling Lc | Method and apparatus for imaging within a living body |
JP2011520570A (en) * | 2008-05-20 | 2011-07-21 | オバリス, インコーポレイテッド | Wire-like and other devices for the treatment of septal defects and systems and methods for delivering the same |
US9603674B2 (en) * | 2008-05-30 | 2017-03-28 | The Regents Of The University Of California | Method to protect the esophagus and other mediastinal structures during cardiac and thoracic interventions |
US8690762B2 (en) * | 2008-06-18 | 2014-04-08 | Raytheon Company | Transparent endoscope head defining a focal length |
JP5157689B2 (en) * | 2008-07-07 | 2013-03-06 | ニプロ株式会社 | Endoscopic surgery device |
US8486735B2 (en) | 2008-07-30 | 2013-07-16 | Raytheon Company | Method and device for incremental wavelength variation to analyze tissue |
WO2010053916A2 (en) | 2008-11-04 | 2010-05-14 | Sterling Lc | Method and device for wavelength shifted imaging |
DE102009002768A1 (en) * | 2009-04-30 | 2010-11-04 | Celon Ag Medical Instruments | Material layer and electrosurgical system for electrosurgical tissue fusion |
US20120029556A1 (en) | 2009-06-22 | 2012-02-02 | Masters Steven J | Sealing device and delivery system |
US8956389B2 (en) | 2009-06-22 | 2015-02-17 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US20120010644A1 (en) * | 2009-07-09 | 2012-01-12 | Sideris Eleftherios B | Method and apparatus for occluding a physiological opening |
US8298218B2 (en) * | 2009-07-29 | 2012-10-30 | Medtronic Cryocath Lp | Compliant balloon |
WO2011041730A2 (en) | 2009-10-01 | 2011-04-07 | Jacobsen Stephen C | Light diffusion apparatus |
WO2011041728A2 (en) | 2009-10-01 | 2011-04-07 | Jacobsen Stephen C | Needle delivered imaging device |
WO2011041720A2 (en) | 2009-10-01 | 2011-04-07 | Jacobsen Stephen C | Method and apparatus for manipulating movement of a micro-catheter |
US8828028B2 (en) | 2009-11-03 | 2014-09-09 | Raytheon Company | Suture device and method for closing a planar opening |
SG10201610494VA (en) | 2009-12-17 | 2017-02-27 | Univ Nanyang Tech | Occlusion Device for Closing Anatomical Defects |
WO2012051489A2 (en) | 2010-10-15 | 2012-04-19 | Cook Medical Technologies Llc | Occlusion device for blocking fluid flow through bodily passages |
JP2012115535A (en) * | 2010-12-02 | 2012-06-21 | Kochi Univ | Medical implement that emits near-infrared fluorescence and medical implement position confirmation system |
US10245049B2 (en) * | 2011-06-08 | 2019-04-02 | Cvdevices, Llc | Thrombus removal systems and devices and methods of using the same |
US9084592B2 (en) * | 2011-07-11 | 2015-07-21 | C2 Therapeutics, Inc. | Focal ablation assembly |
US9770232B2 (en) | 2011-08-12 | 2017-09-26 | W. L. Gore & Associates, Inc. | Heart occlusion devices |
WO2013120082A1 (en) | 2012-02-10 | 2013-08-15 | Kassab Ghassan S | Methods and uses of biological tissues for various stent and other medical applications |
US9821145B2 (en) | 2012-03-23 | 2017-11-21 | Pressure Products Medical Supplies Inc. | Transseptal puncture apparatus and method for using the same |
US10828019B2 (en) | 2013-01-18 | 2020-11-10 | W.L. Gore & Associates, Inc. | Sealing device and delivery system |
WO2014124356A2 (en) | 2013-02-11 | 2014-08-14 | Cook Medical Technologies Llc | Expandable support frame and medical device |
BR122021016202B1 (en) * | 2013-08-07 | 2022-09-06 | Baylis Medical Company Inc | MEDICAL DEVICE AND SYSTEM TO PUNCTURE TISSUES |
JP2015181705A (en) * | 2014-03-24 | 2015-10-22 | テルモ株式会社 | treatment device |
US9808230B2 (en) | 2014-06-06 | 2017-11-07 | W. L. Gore & Associates, Inc. | Sealing device and delivery system |
US10993807B2 (en) | 2017-11-16 | 2021-05-04 | Medtronic Vascular, Inc. | Systems and methods for percutaneously supporting and manipulating a septal wall |
TW202317369A (en) * | 2021-10-22 | 2023-05-01 | 勤倫股份有限公司 | Textiles supporting human motion organs and supportive hot stamping materials providing support and protection for motion organs of human body |
Citations (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US667685A (en) * | 1900-07-20 | 1901-02-12 | Sigmund Willner | Railway-joint. |
US2275167A (en) * | 1939-04-26 | 1942-03-03 | Bierman William | Electrosurgical instrument |
US2580628A (en) * | 1950-07-12 | 1952-01-01 | Bowen & Company Inc | Suction electrode |
US3490442A (en) * | 1966-02-09 | 1970-01-20 | Hellige & Co Gmbh F | Electrode with contact-forming suction cup means |
US3862627A (en) * | 1973-08-16 | 1975-01-28 | Sr Wendel J Hans | Suction electrode |
US3874388A (en) * | 1973-02-12 | 1975-04-01 | Ochsner Med Found Alton | Shunt defect closure system |
US4326529A (en) * | 1978-05-26 | 1982-04-27 | The United States Of America As Represented By The United States Department Of Energy | Corneal-shaping electrode |
US4562838A (en) * | 1981-01-23 | 1986-01-07 | Walker William S | Electrosurgery instrument |
US4590934A (en) * | 1983-05-18 | 1986-05-27 | Jerry L. Malis | Bipolar cutter/coagulator |
US4798594A (en) * | 1987-09-21 | 1989-01-17 | Cordis Corporation | Medical instrument valve |
US4832048A (en) * | 1987-10-29 | 1989-05-23 | Cordis Corporation | Suction ablation catheter |
US4895565A (en) * | 1987-09-21 | 1990-01-23 | Cordis Corporation | Medical instrument valve |
US4900303A (en) * | 1978-03-10 | 1990-02-13 | Lemelson Jerome H | Dispensing catheter and method |
US4911159A (en) * | 1988-11-21 | 1990-03-27 | Johnson Jeffrey W | Electrosurgical instrument with electrical contacts between the probe and the probe holder |
US4919129A (en) * | 1987-11-30 | 1990-04-24 | Celebration Medical Products, Inc. | Extendable electrocautery surgery apparatus and method |
US4929246A (en) * | 1988-10-27 | 1990-05-29 | C. R. Bard, Inc. | Method for closing and sealing an artery after removing a catheter |
US5078717A (en) * | 1989-04-13 | 1992-01-07 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US5099827A (en) * | 1989-12-13 | 1992-03-31 | Richard Wolf Gmbh | Instrument set for closing opened body organs, wounds or the like |
USRE33925E (en) * | 1984-05-22 | 1992-05-12 | Cordis Corporation | Electrosurgical catheter aned method for vascular applications |
US5196007A (en) * | 1991-06-07 | 1993-03-23 | Alan Ellman | Electrosurgical handpiece with activator |
US5195959A (en) * | 1991-05-31 | 1993-03-23 | Paul C. Smith | Electrosurgical device with suction and irrigation |
US5197963A (en) * | 1991-12-02 | 1993-03-30 | Everest Medical Corporation | Electrosurgical instrument with extendable sheath for irrigation and aspiration |
US5207670A (en) * | 1990-06-15 | 1993-05-04 | Rare Earth Medical, Inc. | Photoreactive suturing of biological materials |
US5209756A (en) * | 1989-11-03 | 1993-05-11 | Bahaa Botros Seedhom | Ligament fixation staple |
US5290278A (en) * | 1992-10-20 | 1994-03-01 | Proclosure Inc. | Method and apparatus for applying thermal energy to luminal tissue |
US5292362A (en) * | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5292332A (en) * | 1992-07-27 | 1994-03-08 | Lee Benjamin I | Methods and device for percutanceous sealing of arterial puncture sites |
US5295955A (en) * | 1992-02-14 | 1994-03-22 | Amt, Inc. | Method and apparatus for microwave aided liposuction |
US5300065A (en) * | 1992-11-06 | 1994-04-05 | Proclosure Inc. | Method and apparatus for simultaneously holding and sealing tissue |
US5380304A (en) * | 1991-08-07 | 1995-01-10 | Cook Incorporated | Flexible, kink-resistant, introducer sheath and method of manufacture |
US5383917A (en) * | 1991-07-05 | 1995-01-24 | Jawahar M. Desai | Device and method for multi-phase radio-frequency ablation |
US5405322A (en) * | 1993-08-12 | 1995-04-11 | Boston Scientific Corporation | Method for treating aneurysms with a thermal source |
US5409481A (en) * | 1992-05-21 | 1995-04-25 | Laserscope | Laser tissue welding control system |
US5409479A (en) * | 1983-10-06 | 1995-04-25 | Premier Laser Systems, Inc. | Method for closing tissue wounds using radiative energy beams |
US5500012A (en) * | 1992-07-15 | 1996-03-19 | Angeion Corporation | Ablation catheter system |
US5505730A (en) * | 1994-06-24 | 1996-04-09 | Stuart D. Edwards | Thin layer ablation apparatus |
US5507744A (en) * | 1992-04-23 | 1996-04-16 | Scimed Life Systems, Inc. | Apparatus and method for sealing vascular punctures |
US5611794A (en) * | 1990-10-11 | 1997-03-18 | Lasersurge, Inc. | Clamp for approximating tissue sections |
US5620481A (en) * | 1991-07-05 | 1997-04-15 | Desai; Jawahar M. | Device for multi-phase radio-frequency ablation |
US5626607A (en) * | 1995-04-03 | 1997-05-06 | Heartport, Inc. | Clamp assembly and method of use |
US5709224A (en) * | 1995-06-07 | 1998-01-20 | Radiotherapeutics Corporation | Method and device for permanent vessel occlusion |
US5713891A (en) * | 1995-06-02 | 1998-02-03 | Children's Medical Center Corporation | Modified solder for delivery of bioactive substances and methods of use thereof |
US5725522A (en) * | 1990-06-15 | 1998-03-10 | Rare Earth Medical, Inc. | Laser suturing of biological materials |
US5730742A (en) * | 1994-08-04 | 1998-03-24 | Alto Development Corporation | Inclined, flared, thermally-insulated, anti-clog tip for electrocautery suction tubes |
US5749895A (en) * | 1991-02-13 | 1998-05-12 | Fusion Medical Technologies, Inc. | Method for bonding or fusion of biological tissue and material |
US5855312A (en) * | 1996-07-25 | 1999-01-05 | Toledano; Haviv | Flexible annular stapler for closed surgery of hollow organs |
US5871443A (en) * | 1992-09-25 | 1999-02-16 | Ep Technologies, Inc. | Cardiac mapping and ablation systems |
US6012457A (en) * | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
US6036699A (en) * | 1992-12-10 | 2000-03-14 | Perclose, Inc. | Device and method for suturing tissue |
US6050994A (en) * | 1998-05-05 | 2000-04-18 | Cardiac Pacemakers, Inc. | RF ablation apparatus and method using controllable duty cycle with alternate phasing |
US6056760A (en) * | 1997-01-30 | 2000-05-02 | Nissho Corporation | Device for intracardiac suture |
US6063081A (en) * | 1995-02-22 | 2000-05-16 | Medtronic, Inc. | Fluid-assisted electrocautery device |
US6063085A (en) * | 1992-04-23 | 2000-05-16 | Scimed Life Systems, Inc. | Apparatus and method for sealing vascular punctures |
US6168594B1 (en) * | 1992-11-13 | 2001-01-02 | Scimed Life Systems, Inc. | Electrophysiology RF energy treatment device |
US6171311B1 (en) * | 1996-10-18 | 2001-01-09 | Marc Richelsoph | Transverse connector |
US6211335B1 (en) * | 1995-01-20 | 2001-04-03 | The Microsearch Foundation Of Australia | Method of tissue repair |
US6221068B1 (en) * | 1998-01-15 | 2001-04-24 | Northwestern University | Method for welding tissue |
US6236875B1 (en) * | 1994-10-07 | 2001-05-22 | Surgical Navigation Technologies | Surgical navigation systems including reference and localization frames |
US6355030B1 (en) * | 1998-09-25 | 2002-03-12 | Cardiothoracic Systems, Inc. | Instruments and methods employing thermal energy for the repair and replacement of cardiac valves |
US6358246B1 (en) * | 1999-06-25 | 2002-03-19 | Radiotherapeutics Corporation | Method and system for heating solid tissue |
US6375668B1 (en) * | 1999-06-02 | 2002-04-23 | Hanson S. Gifford | Devices and methods for treating vascular malformations |
US6383198B1 (en) * | 1999-12-07 | 2002-05-07 | Scimed Life System, Inc. | Flexible vacuum grabber for holding lesions |
US6514250B1 (en) * | 2000-04-27 | 2003-02-04 | Medtronic, Inc. | Suction stabilized epicardial ablation devices |
US20030028189A1 (en) * | 1998-08-11 | 2003-02-06 | Arthrocare Corporation | Systems and methods for electrosurgical tissue treatment |
US20030045901A1 (en) * | 2001-09-06 | 2003-03-06 | Nmt Medical, Inc. | Flexible delivery system |
US20030045893A1 (en) * | 2001-09-06 | 2003-03-06 | Integrated Vascular Systems, Inc. | Clip apparatus for closing septal defects and methods of use |
US20030050665A1 (en) * | 2001-09-07 | 2003-03-13 | Integrated Vascular Systems, Inc. | Needle apparatus for closing septal defects and methods for using such apparatus |
US20030065364A1 (en) * | 2001-09-28 | 2003-04-03 | Ethicon, Inc. | Expandable intracardiac return electrode and method of use |
US20030069570A1 (en) * | 1999-10-02 | 2003-04-10 | Witzel Thomas H. | Methods for repairing mitral valve annulus percutaneously |
US20030078578A1 (en) * | 2001-10-22 | 2003-04-24 | Csaba Truckai | Electrosurgical instrument and method of use |
US6682546B2 (en) * | 1994-07-08 | 2004-01-27 | Aga Medical Corporation | Intravascular occlusion devices |
US6692450B1 (en) * | 2000-01-19 | 2004-02-17 | Medtronic Xomed, Inc. | Focused ultrasound ablation devices having selectively actuatable ultrasound emitting elements and methods of using the same |
US6712836B1 (en) * | 1999-05-13 | 2004-03-30 | St. Jude Medical Atg, Inc. | Apparatus and methods for closing septal defects and occluding blood flow |
US6712804B2 (en) * | 1999-09-20 | 2004-03-30 | Ev3 Sunnyvale, Inc. | Method of closing an opening in a wall of the heart |
US6726718B1 (en) * | 1999-12-13 | 2004-04-27 | St. Jude Medical, Inc. | Medical articles prepared for cell adhesion |
US6726696B1 (en) * | 2001-04-24 | 2004-04-27 | Advanced Catheter Engineering, Inc. | Patches and collars for medical applications and methods of use |
US6846319B2 (en) * | 2000-12-14 | 2005-01-25 | Core Medical, Inc. | Devices for sealing openings through tissue and apparatus and methods for delivering them |
US20050021059A1 (en) * | 2000-04-29 | 2005-01-27 | Cole David H. | Magnetic components for use in forming anastomoses, creating ports in vessels and closing openings in tissue |
US20050033327A1 (en) * | 1999-09-07 | 2005-02-10 | John Gainor | Retrievable septal defect closure device |
US20050033288A1 (en) * | 2003-02-13 | 2005-02-10 | Coaptus Medical Corporation | Transseptal left atrial access and septal closure |
US20050034735A1 (en) * | 2003-03-27 | 2005-02-17 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US20050055050A1 (en) * | 2003-07-24 | 2005-03-10 | Alfaro Arthur A. | Intravascular occlusion device |
US20050065506A1 (en) * | 2003-09-12 | 2005-03-24 | Scimed Life Systems, Inc. | Vacuum-based catheter stabilizer |
US20050065509A1 (en) * | 2003-09-22 | 2005-03-24 | Scimed Life Systems, Inc. | Flat electrode arrays for generating flat lesions |
US20050070923A1 (en) * | 2003-09-26 | 2005-03-31 | Mcintosh Scott A. | Device and method for suturing intracardiac defects |
US20050075665A1 (en) * | 2003-09-19 | 2005-04-07 | St. Jude Medical, Inc. | Apparatus and methods for tissue gathering and securing |
US20060009762A1 (en) * | 2002-06-14 | 2006-01-12 | Ablatrics, Inc. | Vacuum coagulation probe for atrial fibrillation treatment |
US20060036284A1 (en) * | 2002-05-06 | 2006-02-16 | Velocimed, Llc | PFO closure devices and related methods of use |
US20060052821A1 (en) * | 2001-09-06 | 2006-03-09 | Ovalis, Inc. | Systems and methods for treating septal defects |
US20060069408A1 (en) * | 2004-09-29 | 2006-03-30 | Terumo Kabushiki Kaisha | Device for treating a patent foramen ovale |
US20060079870A1 (en) * | 2004-10-07 | 2006-04-13 | Barry Robert L | Systems and methods for shrinking and/or securing cardiovascular tissue |
US20060079762A1 (en) * | 2004-10-12 | 2006-04-13 | Norris Peter E | Integrated disease diagnosis and treatment system |
US20060079887A1 (en) * | 2004-10-08 | 2006-04-13 | Buysse Steven P | Electrosurgical system employing multiple electrodes and method thereof |
Family Cites Families (170)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2888928A (en) * | 1957-04-15 | 1959-06-02 | Seiger Harry Wright | Coagulating surgical instrument |
GB1260919A (en) | 1969-02-21 | 1972-01-19 | Spitalul Clinic De Obstetrica | Device for collecting biocurrents of the foetal heart |
US3906955A (en) | 1974-05-06 | 1975-09-23 | Richard R Roberts | Surgical cauterizing tool having suction means |
GB1550676A (en) | 1976-07-07 | 1979-08-15 | Vickers Ltd | Sensing probe for attachment to a body |
US4307720A (en) | 1979-07-26 | 1981-12-29 | Weber Jr Jaroy | Electrocautery apparatus and method and means for cleaning the same |
WO1981003271A1 (en) | 1980-05-13 | 1981-11-26 | American Hospital Supply Corp | A multipolar electrosurgical device |
US4473077A (en) | 1982-05-28 | 1984-09-25 | United States Surgical Corporation | Surgical stapler apparatus with flexible shaft |
US4485817A (en) | 1982-05-28 | 1984-12-04 | United States Surgical Corporation | Surgical stapler apparatus with flexible shaft |
US5370675A (en) | 1992-08-12 | 1994-12-06 | Vidamed, Inc. | Medical probe device and method |
DE3300765C1 (en) | 1983-01-12 | 1983-10-20 | Ingeborg Nieß Elektromedizinische Apparate, 7906 Blaustein | Electrode device for the reduction of electro-physiological voltages |
GB8316194D0 (en) | 1983-06-14 | 1983-07-20 | Medeci Developments Ltd | Electrode holders for current therapy |
US4938218A (en) | 1983-08-30 | 1990-07-03 | Nellcor Incorporated | Perinatal pulse oximetry sensor |
US4682596A (en) | 1984-05-22 | 1987-07-28 | Cordis Corporation | Electrosurgical catheter and method for vascular applications |
HU194499B (en) | 1986-01-08 | 1988-02-29 | Peter Polgar | Electrode-catheter for ablation of his fascicle |
EP0265532B1 (en) | 1986-10-22 | 1990-07-04 | Fukuda Denshi Co., Ltd. | Electrocardiographic electrode pad |
US4796622A (en) | 1987-03-06 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Catheter with oxyhydrogen catalytic thermal tip |
JPS6426784A (en) * | 1987-04-28 | 1989-01-30 | Kanebo Ltd | Method for processing silk fiber |
US4788975B1 (en) | 1987-11-05 | 1999-03-02 | Trimedyne Inc | Control system and method for improved laser angioplasty |
US4884567A (en) | 1987-12-03 | 1989-12-05 | Dimed Inc. | Method for transvenous implantation of objects into the pericardial space of patients |
FR2641003B1 (en) | 1988-12-23 | 1991-04-05 | Tech Milieu Ionisant | |
US5057107A (en) | 1989-04-13 | 1991-10-15 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US4976711A (en) | 1989-04-13 | 1990-12-11 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US5125928A (en) * | 1989-04-13 | 1992-06-30 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US5055100A (en) | 1989-06-19 | 1991-10-08 | Eugene Olsen | Suction attachment for electrosurgical instruments or the like |
US5056517A (en) | 1989-07-24 | 1991-10-15 | Consiglio Nazionale Delle Ricerche | Biomagnetically localizable multipurpose catheter and method for magnetocardiographic guided intracardiac mapping, biopsy and ablation of cardiac arrhythmias |
US5041095A (en) | 1989-12-22 | 1991-08-20 | Cordis Corporation | Hemostasis valve |
GB9008764D0 (en) | 1990-04-19 | 1990-06-13 | Egnell Ameda Ltd | A resilient suction cup |
US5171311A (en) | 1990-04-30 | 1992-12-15 | Everest Medical Corporation | Percutaneous laparoscopic cholecystectomy instrument |
US5071418A (en) | 1990-05-16 | 1991-12-10 | Joseph Rosenbaum | Electrocautery surgical scalpel |
US5540677A (en) | 1990-06-15 | 1996-07-30 | Rare Earth Medical, Inc. | Endoscopic systems for photoreactive suturing of biological materials |
DE4024106C1 (en) | 1990-07-30 | 1992-04-23 | Ethicon Gmbh & Co Kg, 2000 Norderstedt, De | |
WO1992004864A1 (en) | 1990-09-26 | 1992-04-02 | Merwe Marius V D | Monitoring device |
US5086570A (en) * | 1990-09-28 | 1992-02-11 | Screen Printing Enterprises, Inc. | Drying apparatus for screen process printing and coating |
US5042707A (en) | 1990-10-16 | 1991-08-27 | Taheri Syde A | Intravascular stapler, and method of operating same |
US5669934A (en) | 1991-02-13 | 1997-09-23 | Fusion Medical Technologies, Inc. | Methods for joining tissue by applying radiofrequency energy to performed collagen films and sheets |
US5156613A (en) | 1991-02-13 | 1992-10-20 | Interface Biomedical Laboratories Corp. | Collagen welding rod material for use in tissue welding |
WO1992014513A1 (en) | 1991-02-13 | 1992-09-03 | Interface Biomedical Laboratories Corp. | Filler material for use in tissue welding |
US20010051803A1 (en) | 1991-07-05 | 2001-12-13 | Desai Jawahar M. | Device and method for multi-phase radio-frequency ablation |
WO1993005705A1 (en) | 1991-09-19 | 1993-04-01 | Surgicraft Limited | A device for use in monitoring electric signals generated by the human body |
US5290276A (en) * | 1992-02-06 | 1994-03-01 | Sewell Jr Frank | Rotatable laparoscopic puncturing instrument |
WO1993015791A1 (en) | 1992-02-12 | 1993-08-19 | Dimed, Incorporated | System for access to pericardial space |
US5300068A (en) | 1992-04-21 | 1994-04-05 | St. Jude Medical, Inc. | Electrosurgical apparatus |
US5810810A (en) * | 1992-04-23 | 1998-09-22 | Scimed Life Systems, Inc. | Apparatus and method for sealing vascular punctures |
SE9201600L (en) | 1992-05-21 | 1993-11-22 | Siemens Elema Ab | The electrode device |
US5324284A (en) | 1992-06-05 | 1994-06-28 | Cardiac Pathways, Inc. | Endocardial mapping and ablation system utilizing a separately controlled ablation catheter and method |
US5336252A (en) | 1992-06-22 | 1994-08-09 | Cohen Donald M | System and method for implanting cardiac electrical leads |
WO1994000178A1 (en) | 1992-06-26 | 1994-01-06 | Schneider (Usa) Inc. | Catheter with expandable wire mesh tip |
US6398782B1 (en) * | 1992-10-13 | 2002-06-04 | Edwards Lifesciences Corporation | Bipolar vascular sealing apparatus and methods |
US5336221A (en) | 1992-10-14 | 1994-08-09 | Premier Laser Systems, Inc. | Method and apparatus for applying thermal energy to tissue using a clamp |
US5797960A (en) * | 1993-02-22 | 1998-08-25 | Stevens; John H. | Method and apparatus for thoracoscopic intracardiac procedures |
US6832996B2 (en) | 1995-06-07 | 2004-12-21 | Arthrocare Corporation | Electrosurgical systems and methods for treating tissue |
US5571088A (en) * | 1993-07-01 | 1996-11-05 | Boston Scientific Corporation | Ablation catheters |
US5571216A (en) | 1994-01-19 | 1996-11-05 | The General Hospital Corporation | Methods and apparatus for joining collagen-containing materials |
US6092528A (en) | 1994-06-24 | 2000-07-25 | Edwards; Stuart D. | Method to treat esophageal sphincters |
US6302898B1 (en) | 1994-06-24 | 2001-10-16 | Advanced Closure Systems, Inc. | Devices for sealing punctures in body vessels |
US5972023A (en) | 1994-08-15 | 1999-10-26 | Eva Corporation | Implantation device for an aortic graft method of treating aortic aneurysm |
US5931165A (en) | 1994-09-06 | 1999-08-03 | Fusion Medical Technologies, Inc. | Films having improved characteristics and methods for their preparation and use |
US5662643A (en) | 1994-09-28 | 1997-09-02 | Abiomed R & D, Inc. | Laser welding system |
US6087552A (en) | 1994-11-15 | 2000-07-11 | Sisters Of Providence Of Oregon | Method of producing fused biomaterials and tissue |
US5665109A (en) | 1994-12-29 | 1997-09-09 | Yoon; Inbae | Methods and apparatus for suturing tissue |
US6409722B1 (en) * | 1998-07-07 | 2002-06-25 | Medtronic, Inc. | Apparatus and method for creating, maintaining, and controlling a virtual electrode used for the ablation of tissue |
US6456865B2 (en) | 1995-06-08 | 2002-09-24 | Ilan Zadik Samson | Non-invasive medical probe |
NL1001890C2 (en) | 1995-12-13 | 1997-06-17 | Cordis Europ | Catheter with plate-shaped electrode array. |
US6475213B1 (en) | 1996-01-19 | 2002-11-05 | Ep Technologies, Inc. | Method of ablating body tissue |
US5827265A (en) | 1996-02-07 | 1998-10-27 | Regents Of The University Of California | Intraluminal tissue welding for anastomosis |
US5814065A (en) | 1996-02-09 | 1998-09-29 | Cordis Corporation | Suture delivery tool |
US6149660A (en) | 1996-04-22 | 2000-11-21 | Vnus Medical Technologies, Inc. | Method and apparatus for delivery of an appliance in a vessel |
AUPN957296A0 (en) | 1996-04-30 | 1996-05-23 | Cardiac Crc Nominees Pty Limited | A system for simultaneous unipolar multi-electrode ablation |
US5728133A (en) | 1996-07-09 | 1998-03-17 | Cardiologics, L.L.C. | Anchoring device and method for sealing percutaneous punctures in vessels |
US6482224B1 (en) | 1996-08-22 | 2002-11-19 | The Trustees Of Columbia University In The City Of New York | Endovascular flexible stapling device |
US5827268A (en) * | 1996-10-30 | 1998-10-27 | Hearten Medical, Inc. | Device for the treatment of patent ductus arteriosus and method of using the device |
US5972024A (en) | 1996-12-24 | 1999-10-26 | Metacardia, Inc. | Suture-staple apparatus and method |
US6083223A (en) | 1997-08-28 | 2000-07-04 | Baker; James A. | Methods and apparatus for welding blood vessels |
US7094215B2 (en) | 1997-10-02 | 2006-08-22 | Arthrocare Corporation | Systems and methods for electrosurgical tissue contraction |
WO1999018864A1 (en) | 1997-10-10 | 1999-04-22 | Hearten Medical, Inc. | A balloon catheter for abrading a patent foramen ovale and method of using the balloon catheter |
AU9693198A (en) | 1997-10-10 | 1999-05-03 | Hearten Medical, Inc. | A catheter device for abrading a patent foramen ovale and method of using the device |
WO1999018870A1 (en) * | 1997-10-10 | 1999-04-22 | Hearten Medical, Inc. | A balloon catheter for causing thermal trauma to a patent foramen ovale and method of using the balloon catheter |
WO1999018871A1 (en) * | 1997-10-10 | 1999-04-22 | Hearten Medical, Inc. | A catheter for causing thermal trauma to a patent foramen ovale and method of using the catheter |
US6401420B1 (en) * | 1997-11-24 | 2002-06-11 | Darwin Aldis Salls | Tire recycling/disposal system and tire recycling/disposal annulet cylinder or construction block |
US5944738A (en) | 1998-02-06 | 1999-08-31 | Aga Medical Corporation | Percutaneous catheter directed constricting occlusion device |
US6562037B2 (en) * | 1998-02-12 | 2003-05-13 | Boris E. Paton | Bonding of soft biological tissues by passing high frequency electric current therethrough |
US6132429A (en) | 1998-02-17 | 2000-10-17 | Baker; James A. | Radiofrequency medical instrument and methods for luminal welding |
US6325798B1 (en) | 1998-02-19 | 2001-12-04 | Curon Medical, Inc. | Vacuum-assisted systems and methods for treating sphincters and adjoining tissue regions |
JP3799810B2 (en) | 1998-03-30 | 2006-07-19 | ニプロ株式会社 | Transcatheter surgery closure plug and catheter assembly |
AU3475099A (en) | 1998-04-06 | 1999-10-25 | Cornell Research Foundation Inc. | Composition for tissue welding and method of use |
ES2249024T3 (en) | 1998-08-03 | 2006-03-16 | Anson Medical Limited | DEVICES FOR REPAIRING ARTERIES. |
EP1104261A1 (en) | 1998-08-13 | 2001-06-06 | Keravision, Inc. | Corneal electrosurgical probe with a variable-height active site |
US6086586A (en) | 1998-09-14 | 2000-07-11 | Enable Medical Corporation | Bipolar tissue grasping apparatus and tissue welding method |
US6086570A (en) | 1998-09-29 | 2000-07-11 | A-Med Systems, Inc. | Hemostasis valve with membranes having offset apertures |
US6156032A (en) | 1998-09-30 | 2000-12-05 | Scimed Life Systems, Inc. | Method for causing a stricture of a body passageway |
WO2000019926A1 (en) | 1998-10-05 | 2000-04-13 | Scimed Life Systems, Inc. | Large area thermal ablation |
US5919200A (en) * | 1998-10-09 | 1999-07-06 | Hearten Medical, Inc. | Balloon catheter for abrading a patent foramen ovale and method of using the balloon catheter |
US6398779B1 (en) * | 1998-10-23 | 2002-06-04 | Sherwood Services Ag | Vessel sealing system |
US7128073B1 (en) * | 1998-11-06 | 2006-10-31 | Ev3 Endovascular, Inc. | Method and device for left atrial appendage occlusion |
US6423057B1 (en) | 1999-01-25 | 2002-07-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method and apparatus for monitoring and controlling tissue temperature and lesion formation in radio-frequency ablation procedures |
US6248124B1 (en) * | 1999-02-22 | 2001-06-19 | Tyco Healthcare Group | Arterial hole closure apparatus |
US6257241B1 (en) | 1999-03-31 | 2001-07-10 | Ethicon Endo-Surgery, Inc. | Method for repairing tissue defects using ultrasonic radio frequency energy |
US6606523B1 (en) | 1999-04-14 | 2003-08-12 | Transneuronix Inc. | Gastric stimulator apparatus and method for installing |
AU775394B2 (en) | 1999-07-19 | 2004-07-29 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Apparatus and method for ablating tissue |
US7526342B2 (en) | 1999-08-10 | 2009-04-28 | Maquet Cardiovascular Llc | Apparatus for endoscopic cardiac mapping and lead placement |
US6391049B1 (en) * | 1999-10-06 | 2002-05-21 | Board Of Regents The University Of Texas System | Solid biodegradable device for use in tissue repair |
US6551303B1 (en) * | 1999-10-27 | 2003-04-22 | Atritech, Inc. | Barrier device for ostium of left atrial appendage |
US6790218B2 (en) | 1999-12-23 | 2004-09-14 | Swaminathan Jayaraman | Occlusive coil manufacture and delivery |
US6391048B1 (en) * | 2000-01-05 | 2002-05-21 | Integrated Vascular Systems, Inc. | Integrated vascular device with puncture site closure component and sealant and methods of use |
US6451013B1 (en) | 2000-01-19 | 2002-09-17 | Medtronic Xomed, Inc. | Methods of tonsil reduction using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
US6413254B1 (en) | 2000-01-19 | 2002-07-02 | Medtronic Xomed, Inc. | Method of tongue reduction by thermal ablation using high intensity focused ultrasound |
US6409720B1 (en) | 2000-01-19 | 2002-06-25 | Medtronic Xomed, Inc. | Methods of tongue reduction using high intensity focused ultrasound to form an ablated tissue area containing a plurality of lesions |
EP1253857B1 (en) * | 2000-02-03 | 2009-01-21 | Tissuemed Limited | Device for the closure of a surgical puncture |
GB2359024A (en) | 2000-02-09 | 2001-08-15 | Anson Medical Ltd | Fixator for arteries |
US6558314B1 (en) * | 2000-02-11 | 2003-05-06 | Iotek, Inc. | Devices and method for manipulation of organ tissue |
US6641604B1 (en) | 2000-02-11 | 2003-11-04 | Iotek, Inc. | Devices and method for manipulation of organ tissue |
US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US6650923B1 (en) | 2000-04-13 | 2003-11-18 | Ev3 Sunnyvale, Inc. | Method for accessing the left atrium of the heart by locating the fossa ovalis |
US6551344B2 (en) * | 2000-04-26 | 2003-04-22 | Ev3 Inc. | Septal defect occluder |
AU2001249874A1 (en) | 2000-04-27 | 2001-11-12 | Medtronic, Inc. | System and method for assessing transmurality of ablation lesions |
US6558382B2 (en) * | 2000-04-27 | 2003-05-06 | Medtronic, Inc. | Suction stabilized epicardial ablation devices |
US8486065B2 (en) | 2000-06-07 | 2013-07-16 | Wisconsin Alumni Research Foundation | Radio-frequency ablation system and method using multiple electrodes |
US6645225B1 (en) | 2000-11-01 | 2003-11-11 | Alvan W. Atkinson | Method and apparatus for plugging a patent foramen ovale formed in the heart |
US6695867B2 (en) | 2002-02-21 | 2004-02-24 | Integrated Vascular Systems, Inc. | Plunger apparatus and methods for delivering a closure device |
US6837848B2 (en) | 2003-01-15 | 2005-01-04 | Medtronic, Inc. | Methods and apparatus for accessing and stabilizing an area of the heart |
US20020143322A1 (en) | 2001-01-23 | 2002-10-03 | Haghighi Ali Z. | Apparatus and method for shrinking collagen |
US6699245B2 (en) | 2001-02-05 | 2004-03-02 | A-Med Systems, Inc. | Anastomosis system and related methods |
US7473224B2 (en) | 2001-05-29 | 2009-01-06 | Ethicon Endo-Surgery, Inc. | Deployable ultrasound medical transducers |
US7338514B2 (en) * | 2001-06-01 | 2008-03-04 | St. Jude Medical, Cardiology Division, Inc. | Closure devices, related delivery methods and tools, and related methods of use |
US20050267495A1 (en) | 2004-05-17 | 2005-12-01 | Gateway Medical, Inc. | Systems and methods for closing internal tissue defects |
US6652518B2 (en) | 2001-09-28 | 2003-11-25 | Ethicon, Inc. | Transmural ablation tool and method |
US6893431B2 (en) * | 2001-10-15 | 2005-05-17 | Scimed Life Systems, Inc. | Medical device for delivering patches |
US6929644B2 (en) | 2001-10-22 | 2005-08-16 | Surgrx Inc. | Electrosurgical jaw structure for controlled energy delivery |
US6770072B1 (en) | 2001-10-22 | 2004-08-03 | Surgrx, Inc. | Electrosurgical jaw structure for controlled energy delivery |
US6926716B2 (en) | 2001-11-09 | 2005-08-09 | Surgrx Inc. | Electrosurgical instrument |
US6669693B2 (en) | 2001-11-13 | 2003-12-30 | Mayo Foundation For Medical Education And Research | Tissue ablation device and methods of using |
US6575971B2 (en) * | 2001-11-15 | 2003-06-10 | Quantum Cor, Inc. | Cardiac valve leaflet stapler device and methods thereof |
US6849075B2 (en) * | 2001-12-04 | 2005-02-01 | Estech, Inc. | Cardiac ablation devices and methods |
EP1467661A4 (en) | 2001-12-19 | 2008-11-05 | Nmt Medical Inc | Septal occluder and associated methods |
JP2005525843A (en) * | 2002-01-14 | 2005-09-02 | エヌエムティー メディカル インコーポレイテッド | Patent foramen ovale (PFO) occlusion method and apparatus |
US6733498B2 (en) * | 2002-02-19 | 2004-05-11 | Live Tissue Connect, Inc. | System and method for control of tissue welding |
JP2005521447A (en) | 2002-03-25 | 2005-07-21 | エヌエムティー メディカル インコーポレイテッド | Closure clip of patent foramen ovale (PFO) |
AU2003253620A1 (en) * | 2002-06-03 | 2003-12-19 | Nmt Medical, Inc. | Device with biological tissue scaffold for intracardiac defect closure |
US7063698B2 (en) | 2002-06-14 | 2006-06-20 | Ncontact Surgical, Inc. | Vacuum coagulation probes |
US20040044391A1 (en) | 2002-08-29 | 2004-03-04 | Stephen Porter | Device for closure of a vascular defect and method of treating the same |
US7208003B2 (en) * | 2002-09-20 | 2007-04-24 | Cordis Neurovascular, Inc. | Reattachable introducer for a medical device deployment system |
CA2499753A1 (en) * | 2002-09-23 | 2004-04-01 | Nmt Medical, Inc. | Septal puncture device |
US6755790B2 (en) | 2002-10-14 | 2004-06-29 | Medtronic, Inc. | Transseptal access tissue thickness sensing dilator devices and methods for fabricating and using same |
EP1560525B1 (en) | 2002-11-07 | 2009-01-14 | NMT Medical, Inc. | Patent foramen ovale (pfo) closure with magnetic force |
US7172562B2 (en) * | 2002-11-22 | 2007-02-06 | Mckinley Laurence M | System, method and apparatus for locating, measuring and evaluating the enlargement of a foramen |
CA2503666A1 (en) | 2002-12-09 | 2004-06-24 | Nmt Medical, Inc. | Septal closure devices |
US6960224B2 (en) | 2003-01-22 | 2005-11-01 | Cardia, Inc. | Laminated sheets for use in a fully retrievable occlusion device |
WO2004069055A2 (en) | 2003-02-04 | 2004-08-19 | Ev3 Sunnyvale Inc. | Patent foramen ovale closure system |
EP1605865B1 (en) | 2003-03-17 | 2008-12-10 | ev3 Endovascular, Inc. | Stent with thin film composite laminate |
US7293562B2 (en) | 2003-03-27 | 2007-11-13 | Cierra, Inc. | Energy based devices and methods for treatment of anatomic tissue defects |
US7972330B2 (en) | 2003-03-27 | 2011-07-05 | Terumo Kabushiki Kaisha | Methods and apparatus for closing a layered tissue defect |
US7186251B2 (en) * | 2003-03-27 | 2007-03-06 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US6939348B2 (en) | 2003-03-27 | 2005-09-06 | Cierra, Inc. | Energy based devices and methods for treatment of patent foramen ovale |
US8021362B2 (en) | 2003-03-27 | 2011-09-20 | Terumo Kabushiki Kaisha | Methods and apparatus for closing a layered tissue defect |
EP2455037A1 (en) * | 2003-03-27 | 2012-05-23 | Terumo Kabushiki Kaisha | Methods and apparatus for treatment of patent foramen ovale |
US20040267306A1 (en) | 2003-04-11 | 2004-12-30 | Velocimed, L.L.C. | Closure devices, related delivery methods, and related methods of use |
US7238182B2 (en) | 2003-04-25 | 2007-07-03 | Medtronic, Inc. | Device and method for transurethral prostate treatment |
US7311701B2 (en) | 2003-06-10 | 2007-12-25 | Cierra, Inc. | Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound |
ES2436596T3 (en) | 2003-07-14 | 2014-01-03 | W.L. Gore & Associates, Inc. | Oval foramen tubular permeable closure device (FOP) with retention system |
US20050192627A1 (en) | 2003-10-10 | 2005-09-01 | Whisenant Brian K. | Patent foramen ovale closure devices, delivery apparatus and related methods and systems |
US20050125032A1 (en) | 2003-10-10 | 2005-06-09 | Whisenant Brian K. | Patent foramen ovale (PFO) closure devices, delivery apparatus and related methods and systems |
US8190248B2 (en) | 2003-10-16 | 2012-05-29 | Louisiana Tech University Foundation, Inc. | Medical devices for the detection, prevention and/or treatment of neurological disorders, and methods related thereto |
EP1867287B8 (en) | 2003-10-24 | 2011-10-05 | Tyco Healthcare Group LP | Patent foramen ovale closure system |
WO2005074517A2 (en) | 2004-01-30 | 2005-08-18 | Nmt Medical, Inc. | Welding systems for closure of cardiac openings |
US20050192626A1 (en) | 2004-01-30 | 2005-09-01 | Nmt Medical, Inc. | Devices, systems, and methods for closure of cardiac openings |
US7282051B2 (en) | 2004-02-04 | 2007-10-16 | Boston Scientific Scimed, Inc. | Ablation probe for delivering fluid through porous structure |
US20050187568A1 (en) | 2004-02-20 | 2005-08-25 | Klenk Alan R. | Devices and methods for closing a patent foramen ovale with a coil-shaped closure device |
US8361110B2 (en) | 2004-04-26 | 2013-01-29 | W.L. Gore & Associates, Inc. | Heart-shaped PFO closure device |
US20050256532A1 (en) | 2004-05-12 | 2005-11-17 | Asha Nayak | Cardiovascular defect patch device and method |
US20080140113A1 (en) | 2006-12-07 | 2008-06-12 | Cierra, Inc. | Method for sealing a pfo using an energy delivery device |
-
2003
- 2003-09-18 US US10/665,974 patent/US7165552B2/en active Active
-
2004
- 2004-03-26 WO PCT/US2004/009533 patent/WO2004086951A2/en active Application Filing
- 2004-03-26 EP EP04758521A patent/EP1605851A4/en not_active Withdrawn
- 2004-03-26 CA CA002519558A patent/CA2519558A1/en not_active Abandoned
- 2004-03-26 AU AU2004226398A patent/AU2004226398B2/en not_active Ceased
- 2004-03-26 JP JP2006509418A patent/JP4318718B2/en not_active Expired - Lifetime
-
2006
- 2006-08-15 US US11/464,746 patent/US8057469B2/en active Active
- 2006-08-17 US US11/506,232 patent/US20070044811A1/en not_active Abandoned
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US667685A (en) * | 1900-07-20 | 1901-02-12 | Sigmund Willner | Railway-joint. |
US2275167A (en) * | 1939-04-26 | 1942-03-03 | Bierman William | Electrosurgical instrument |
US2580628A (en) * | 1950-07-12 | 1952-01-01 | Bowen & Company Inc | Suction electrode |
US3490442A (en) * | 1966-02-09 | 1970-01-20 | Hellige & Co Gmbh F | Electrode with contact-forming suction cup means |
US3874388A (en) * | 1973-02-12 | 1975-04-01 | Ochsner Med Found Alton | Shunt defect closure system |
US3862627A (en) * | 1973-08-16 | 1975-01-28 | Sr Wendel J Hans | Suction electrode |
US4900303A (en) * | 1978-03-10 | 1990-02-13 | Lemelson Jerome H | Dispensing catheter and method |
US4326529A (en) * | 1978-05-26 | 1982-04-27 | The United States Of America As Represented By The United States Department Of Energy | Corneal-shaping electrode |
US4562838A (en) * | 1981-01-23 | 1986-01-07 | Walker William S | Electrosurgery instrument |
US4590934A (en) * | 1983-05-18 | 1986-05-27 | Jerry L. Malis | Bipolar cutter/coagulator |
US5409479A (en) * | 1983-10-06 | 1995-04-25 | Premier Laser Systems, Inc. | Method for closing tissue wounds using radiative energy beams |
USRE33925E (en) * | 1984-05-22 | 1992-05-12 | Cordis Corporation | Electrosurgical catheter aned method for vascular applications |
US4895565A (en) * | 1987-09-21 | 1990-01-23 | Cordis Corporation | Medical instrument valve |
US4798594A (en) * | 1987-09-21 | 1989-01-17 | Cordis Corporation | Medical instrument valve |
US4832048A (en) * | 1987-10-29 | 1989-05-23 | Cordis Corporation | Suction ablation catheter |
US4919129A (en) * | 1987-11-30 | 1990-04-24 | Celebration Medical Products, Inc. | Extendable electrocautery surgery apparatus and method |
US4929246A (en) * | 1988-10-27 | 1990-05-29 | C. R. Bard, Inc. | Method for closing and sealing an artery after removing a catheter |
US4911159A (en) * | 1988-11-21 | 1990-03-27 | Johnson Jeffrey W | Electrosurgical instrument with electrical contacts between the probe and the probe holder |
US5078717A (en) * | 1989-04-13 | 1992-01-07 | Everest Medical Corporation | Ablation catheter with selectively deployable electrodes |
US5209756A (en) * | 1989-11-03 | 1993-05-11 | Bahaa Botros Seedhom | Ligament fixation staple |
US5099827A (en) * | 1989-12-13 | 1992-03-31 | Richard Wolf Gmbh | Instrument set for closing opened body organs, wounds or the like |
US5725522A (en) * | 1990-06-15 | 1998-03-10 | Rare Earth Medical, Inc. | Laser suturing of biological materials |
US5207670A (en) * | 1990-06-15 | 1993-05-04 | Rare Earth Medical, Inc. | Photoreactive suturing of biological materials |
US5292362A (en) * | 1990-07-27 | 1994-03-08 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5611794A (en) * | 1990-10-11 | 1997-03-18 | Lasersurge, Inc. | Clamp for approximating tissue sections |
US5749895A (en) * | 1991-02-13 | 1998-05-12 | Fusion Medical Technologies, Inc. | Method for bonding or fusion of biological tissue and material |
US5195959A (en) * | 1991-05-31 | 1993-03-23 | Paul C. Smith | Electrosurgical device with suction and irrigation |
US5196007A (en) * | 1991-06-07 | 1993-03-23 | Alan Ellman | Electrosurgical handpiece with activator |
US5620481A (en) * | 1991-07-05 | 1997-04-15 | Desai; Jawahar M. | Device for multi-phase radio-frequency ablation |
US5383917A (en) * | 1991-07-05 | 1995-01-24 | Jawahar M. Desai | Device and method for multi-phase radio-frequency ablation |
US5380304A (en) * | 1991-08-07 | 1995-01-10 | Cook Incorporated | Flexible, kink-resistant, introducer sheath and method of manufacture |
US5197963A (en) * | 1991-12-02 | 1993-03-30 | Everest Medical Corporation | Electrosurgical instrument with extendable sheath for irrigation and aspiration |
US5295955A (en) * | 1992-02-14 | 1994-03-22 | Amt, Inc. | Method and apparatus for microwave aided liposuction |
US6063085A (en) * | 1992-04-23 | 2000-05-16 | Scimed Life Systems, Inc. | Apparatus and method for sealing vascular punctures |
US5507744A (en) * | 1992-04-23 | 1996-04-16 | Scimed Life Systems, Inc. | Apparatus and method for sealing vascular punctures |
US5409481A (en) * | 1992-05-21 | 1995-04-25 | Laserscope | Laser tissue welding control system |
US5500012A (en) * | 1992-07-15 | 1996-03-19 | Angeion Corporation | Ablation catheter system |
US5292332A (en) * | 1992-07-27 | 1994-03-08 | Lee Benjamin I | Methods and device for percutanceous sealing of arterial puncture sites |
US5871443A (en) * | 1992-09-25 | 1999-02-16 | Ep Technologies, Inc. | Cardiac mapping and ablation systems |
US5290278A (en) * | 1992-10-20 | 1994-03-01 | Proclosure Inc. | Method and apparatus for applying thermal energy to luminal tissue |
US5300065A (en) * | 1992-11-06 | 1994-04-05 | Proclosure Inc. | Method and apparatus for simultaneously holding and sealing tissue |
US6168594B1 (en) * | 1992-11-13 | 2001-01-02 | Scimed Life Systems, Inc. | Electrophysiology RF energy treatment device |
US6036699A (en) * | 1992-12-10 | 2000-03-14 | Perclose, Inc. | Device and method for suturing tissue |
US5405322A (en) * | 1993-08-12 | 1995-04-11 | Boston Scientific Corporation | Method for treating aneurysms with a thermal source |
US5505730A (en) * | 1994-06-24 | 1996-04-09 | Stuart D. Edwards | Thin layer ablation apparatus |
US6682546B2 (en) * | 1994-07-08 | 2004-01-27 | Aga Medical Corporation | Intravascular occlusion devices |
US5730742A (en) * | 1994-08-04 | 1998-03-24 | Alto Development Corporation | Inclined, flared, thermally-insulated, anti-clog tip for electrocautery suction tubes |
US6236875B1 (en) * | 1994-10-07 | 2001-05-22 | Surgical Navigation Technologies | Surgical navigation systems including reference and localization frames |
US6211335B1 (en) * | 1995-01-20 | 2001-04-03 | The Microsearch Foundation Of Australia | Method of tissue repair |
US6063081A (en) * | 1995-02-22 | 2000-05-16 | Medtronic, Inc. | Fluid-assisted electrocautery device |
US6716211B2 (en) * | 1995-02-22 | 2004-04-06 | Medtronic, Inc. | Medical device with porous metal element |
US5626607A (en) * | 1995-04-03 | 1997-05-06 | Heartport, Inc. | Clamp assembly and method of use |
US5713891A (en) * | 1995-06-02 | 1998-02-03 | Children's Medical Center Corporation | Modified solder for delivery of bioactive substances and methods of use thereof |
US5709224A (en) * | 1995-06-07 | 1998-01-20 | Radiotherapeutics Corporation | Method and device for permanent vessel occlusion |
US5855312A (en) * | 1996-07-25 | 1999-01-05 | Toledano; Haviv | Flexible annular stapler for closed surgery of hollow organs |
US6171311B1 (en) * | 1996-10-18 | 2001-01-09 | Marc Richelsoph | Transverse connector |
US6056760A (en) * | 1997-01-30 | 2000-05-02 | Nissho Corporation | Device for intracardiac suture |
US6012457A (en) * | 1997-07-08 | 2000-01-11 | The Regents Of The University Of California | Device and method for forming a circumferential conduction block in a pulmonary vein |
US6221068B1 (en) * | 1998-01-15 | 2001-04-24 | Northwestern University | Method for welding tissue |
US6050994A (en) * | 1998-05-05 | 2000-04-18 | Cardiac Pacemakers, Inc. | RF ablation apparatus and method using controllable duty cycle with alternate phasing |
US20030028189A1 (en) * | 1998-08-11 | 2003-02-06 | Arthrocare Corporation | Systems and methods for electrosurgical tissue treatment |
US6355030B1 (en) * | 1998-09-25 | 2002-03-12 | Cardiothoracic Systems, Inc. | Instruments and methods employing thermal energy for the repair and replacement of cardiac valves |
US6712836B1 (en) * | 1999-05-13 | 2004-03-30 | St. Jude Medical Atg, Inc. | Apparatus and methods for closing septal defects and occluding blood flow |
US6375668B1 (en) * | 1999-06-02 | 2002-04-23 | Hanson S. Gifford | Devices and methods for treating vascular malformations |
US6358246B1 (en) * | 1999-06-25 | 2002-03-19 | Radiotherapeutics Corporation | Method and system for heating solid tissue |
US20050033327A1 (en) * | 1999-09-07 | 2005-02-10 | John Gainor | Retrievable septal defect closure device |
US7025756B2 (en) * | 1999-09-20 | 2006-04-11 | Ev 3 Sunnyvale, Inc. | Method of securing tissue |
US6712804B2 (en) * | 1999-09-20 | 2004-03-30 | Ev3 Sunnyvale, Inc. | Method of closing an opening in a wall of the heart |
US20030069570A1 (en) * | 1999-10-02 | 2003-04-10 | Witzel Thomas H. | Methods for repairing mitral valve annulus percutaneously |
US20040059347A1 (en) * | 1999-12-07 | 2004-03-25 | Peter Hamilton | Flexible vacuum grabber for holding lesions |
US6383198B1 (en) * | 1999-12-07 | 2002-05-07 | Scimed Life System, Inc. | Flexible vacuum grabber for holding lesions |
US6726718B1 (en) * | 1999-12-13 | 2004-04-27 | St. Jude Medical, Inc. | Medical articles prepared for cell adhesion |
US6692450B1 (en) * | 2000-01-19 | 2004-02-17 | Medtronic Xomed, Inc. | Focused ultrasound ablation devices having selectively actuatable ultrasound emitting elements and methods of using the same |
US6514250B1 (en) * | 2000-04-27 | 2003-02-04 | Medtronic, Inc. | Suction stabilized epicardial ablation devices |
US20050021059A1 (en) * | 2000-04-29 | 2005-01-27 | Cole David H. | Magnetic components for use in forming anastomoses, creating ports in vessels and closing openings in tissue |
US6846319B2 (en) * | 2000-12-14 | 2005-01-25 | Core Medical, Inc. | Devices for sealing openings through tissue and apparatus and methods for delivering them |
US6726696B1 (en) * | 2001-04-24 | 2004-04-27 | Advanced Catheter Engineering, Inc. | Patches and collars for medical applications and methods of use |
US20030045893A1 (en) * | 2001-09-06 | 2003-03-06 | Integrated Vascular Systems, Inc. | Clip apparatus for closing septal defects and methods of use |
US20030045901A1 (en) * | 2001-09-06 | 2003-03-06 | Nmt Medical, Inc. | Flexible delivery system |
US20060052821A1 (en) * | 2001-09-06 | 2006-03-09 | Ovalis, Inc. | Systems and methods for treating septal defects |
US6702835B2 (en) * | 2001-09-07 | 2004-03-09 | Core Medical, Inc. | Needle apparatus for closing septal defects and methods for using such apparatus |
US20030050665A1 (en) * | 2001-09-07 | 2003-03-13 | Integrated Vascular Systems, Inc. | Needle apparatus for closing septal defects and methods for using such apparatus |
US20030065364A1 (en) * | 2001-09-28 | 2003-04-03 | Ethicon, Inc. | Expandable intracardiac return electrode and method of use |
US20030078578A1 (en) * | 2001-10-22 | 2003-04-24 | Csaba Truckai | Electrosurgical instrument and method of use |
US20060036284A1 (en) * | 2002-05-06 | 2006-02-16 | Velocimed, Llc | PFO closure devices and related methods of use |
US20060009762A1 (en) * | 2002-06-14 | 2006-01-12 | Ablatrics, Inc. | Vacuum coagulation probe for atrial fibrillation treatment |
US20070088355A9 (en) * | 2003-02-13 | 2007-04-19 | Coaptus Medical Corporation | Transseptal left atrial access and septal closure |
US20050033288A1 (en) * | 2003-02-13 | 2005-02-10 | Coaptus Medical Corporation | Transseptal left atrial access and septal closure |
US7165552B2 (en) * | 2003-03-27 | 2007-01-23 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US20050034735A1 (en) * | 2003-03-27 | 2005-02-17 | Cierra, Inc. | Methods and apparatus for treatment of patent foramen ovale |
US20050055050A1 (en) * | 2003-07-24 | 2005-03-10 | Alfaro Arthur A. | Intravascular occlusion device |
US20050065506A1 (en) * | 2003-09-12 | 2005-03-24 | Scimed Life Systems, Inc. | Vacuum-based catheter stabilizer |
US20050075665A1 (en) * | 2003-09-19 | 2005-04-07 | St. Jude Medical, Inc. | Apparatus and methods for tissue gathering and securing |
US20050065509A1 (en) * | 2003-09-22 | 2005-03-24 | Scimed Life Systems, Inc. | Flat electrode arrays for generating flat lesions |
US20050070923A1 (en) * | 2003-09-26 | 2005-03-31 | Mcintosh Scott A. | Device and method for suturing intracardiac defects |
US20060069408A1 (en) * | 2004-09-29 | 2006-03-30 | Terumo Kabushiki Kaisha | Device for treating a patent foramen ovale |
US20060079870A1 (en) * | 2004-10-07 | 2006-04-13 | Barry Robert L | Systems and methods for shrinking and/or securing cardiovascular tissue |
US20060079887A1 (en) * | 2004-10-08 | 2006-04-13 | Buysse Steven P | Electrosurgical system employing multiple electrodes and method thereof |
US20060079762A1 (en) * | 2004-10-12 | 2006-04-13 | Norris Peter E | Integrated disease diagnosis and treatment system |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080009859A1 (en) * | 2003-02-13 | 2008-01-10 | Coaptus Medical Corporation | Transseptal left atrial access and septal closure |
US8758395B2 (en) * | 2003-05-19 | 2014-06-24 | Septrx, Inc. | Embolic filtering method and apparatus |
US20060009799A1 (en) * | 2003-05-19 | 2006-01-12 | Kleshinski Stephen J | Embolic filtering method and apparatus |
US7797056B2 (en) * | 2005-09-06 | 2010-09-14 | Nmt Medical, Inc. | Removable intracardiac RF device |
US20070055333A1 (en) * | 2005-09-06 | 2007-03-08 | Sean Forde | Removable intracardiac RF device |
US8795329B2 (en) | 2005-09-06 | 2014-08-05 | W.L. Gore & Associates, Inc. | Removable intracardiac RF device |
US20080215085A1 (en) * | 2005-09-26 | 2008-09-04 | Whisenant Brian K | Compliant Electrode for Patent Foramen Ovale Closure Device |
US20110093037A1 (en) * | 2005-09-26 | 2011-04-21 | Coherex Medical, Inc. | Compliant electrode for patent foramen ovale closure device |
US7799023B2 (en) | 2005-09-26 | 2010-09-21 | Coherex Medical, Inc. | Compliant electrode for patent foramen ovale closure device |
US8221405B2 (en) | 2006-02-06 | 2012-07-17 | Coherex Medical, Inc. | Patent foramen ovale closure device and methods for determining RF dose for patent foramen ovale closure |
US20080045937A1 (en) * | 2006-02-06 | 2008-02-21 | Whisenant Brian K | Patent foramen ovale closure device and methods for determining rf dose for patent foramen ovale closure |
US9044247B2 (en) | 2006-02-24 | 2015-06-02 | Terumo Kabushiki Kaisha | PFO closing device |
US8574265B2 (en) | 2006-02-24 | 2013-11-05 | Terumo Kabushiki Kaisha | PFO closing device |
US8603139B2 (en) | 2006-02-24 | 2013-12-10 | Terumo Kabushiki Kaisha | PFO closing device |
US8172839B2 (en) | 2006-02-24 | 2012-05-08 | Terumo Kabushiki Kaisha | PFO closing device |
US8402974B2 (en) | 2006-05-30 | 2013-03-26 | Coherex Medical, Inc. | Methods, systems, and devices for sensing, measuring, and controlling closure of a patent foramen ovale |
US20080033421A1 (en) * | 2006-05-30 | 2008-02-07 | Coherex Medical, Inc. | Methods, systems, and devices for closing a patent foramen ovale using mechanical structures |
US7938826B2 (en) | 2006-05-30 | 2011-05-10 | Coherex Medical, Inc. | Methods, systems, and devices for closing a patent foramen ovale using mechanical structures |
US20080033425A1 (en) * | 2006-05-30 | 2008-02-07 | Coherex Medical, Inc. | Methods, systems, and devices for sensing, measuring, and controlling closure of a patent foramen ovale |
US20110213364A1 (en) * | 2006-05-30 | 2011-09-01 | Coherex Medical, Inc. | Methods, systems, and devices for closing a patent foramen ovale using mechanical structures |
US20090005776A1 (en) * | 2007-06-25 | 2009-01-01 | Terumo Kabushiki Kaisha | Medical device |
US8382752B2 (en) | 2007-06-25 | 2013-02-26 | Terumo Kabushiki Kaisha | Medical device |
US8394090B2 (en) | 2007-06-25 | 2013-03-12 | Terumo Kabushiki Kaisha | Medical device |
US8460287B2 (en) | 2007-08-28 | 2013-06-11 | Terumo Kabushiki Kaisha | PFO closing device |
US8597294B2 (en) | 2007-08-28 | 2013-12-03 | Terumo Kabushiki Kaisha | Biological tissue closing device |
US20090069810A1 (en) * | 2007-08-28 | 2009-03-12 | Terumo Kabushiki Kaisha | Biological tissue closing device |
US20090069809A1 (en) * | 2007-08-28 | 2009-03-12 | Terumo Kabushiki Kaisha | Pfo closing device |
US20090076525A1 (en) * | 2007-08-28 | 2009-03-19 | Terumo Kabushiki Kaisha | Pfo closing device |
US8920418B2 (en) | 2007-08-28 | 2014-12-30 | Terumo Kabushiki Kaisha | PFO closing device |
US8182481B2 (en) | 2007-08-28 | 2012-05-22 | Terumo Kabushiki Kaisha | PFO closing device |
Also Published As
Publication number | Publication date |
---|---|
US7165552B2 (en) | 2007-01-23 |
CA2519558A1 (en) | 2004-10-14 |
EP1605851A4 (en) | 2010-09-29 |
US8057469B2 (en) | 2011-11-15 |
AU2004226398B2 (en) | 2009-02-26 |
US20050034735A1 (en) | 2005-02-17 |
JP4318718B2 (en) | 2009-08-26 |
AU2004226398A1 (en) | 2004-10-14 |
WO2004086951A2 (en) | 2004-10-14 |
US20070078485A1 (en) | 2007-04-05 |
WO2004086951A3 (en) | 2005-05-06 |
EP1605851A2 (en) | 2005-12-21 |
JP2006521189A (en) | 2006-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7165552B2 (en) | Methods and apparatus for treatment of patent foramen ovale | |
US7914527B2 (en) | Energy based devices and methods for treatment of patent foramen ovale | |
US8038672B2 (en) | Energy based devices and methods for treatment of patent foramen ovale | |
US7972330B2 (en) | Methods and apparatus for closing a layered tissue defect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TERUMO KABUSHIKI KAISHA, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CIERRA, INC.;REEL/FRAME:020930/0649 Effective date: 20080505 Owner name: TERUMO KABUSHIKI KAISHA,JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CIERRA, INC.;REEL/FRAME:020930/0649 Effective date: 20080505 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |